

Validity and utility of Hierarchical Taxonomy of Psychopathology (HiTOP): I. Psychosis superspectrum

Roman Kotov¹, Katherine G. Jonas¹, William T. Carpenter², Michael N. Dretsch³, Nicholas R. Eaton⁴, Miriam K. Forbes⁵, Kelsie T. Forbush⁶, Kelsey Hobbs⁷, Ulrich Reininghaus⁸⁻¹⁰, Tim Slade¹¹, Susan C. South¹², Matthew Sunderland¹¹, Monika A. Waszczuk¹, Thomas A. Widiger¹³, Aidan G.C. Wright¹⁴, David H. Zald¹⁵, Robert F. Krueger⁷, David Watson¹⁶; HiTOP Utility Workgroup*

¹Department of Psychiatry, Stony Brook University, Stony Brook, NY, USA; ²Department of Psychiatry, University of Maryland, Baltimore, MD, USA; ³Walter Reed Army Institute of Research, US Army Medical Research Directorate - West, Silver Spring, MD, USA; ⁴Department of Psychology, Stony Brook University, Stony Brook, NY, USA; ⁵Department of Psychology, Macquarie University, Sydney, Australia; ⁶Department of Psychology, University of Kansas, Lawrence, KS, USA; ⁷Department of Psychology, University of Minnesota, Minneapolis, MN, USA; ⁸Department of Public Mental Health, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany; ⁹ESRC Centre for Society and Mental Health, King's College London, London, UK; ¹⁰Centre for Epidemiology and Public Health, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; ¹¹Matilda Centre for Research in Mental Health and Substance Abuse, University of Sydney, Sydney, NSW, Australia; ¹²Department of Psychological Sciences, Purdue University, West Lafayette, IN, USA; ¹³Department of Psychology, University of Kentucky, Lexington, KY, USA; ¹⁴Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA; ¹⁵Department of Psychology, Vanderbilt University, Nashville, TN, USA; ¹⁶Department of Psychology, University of Notre Dame, South Bend, IN, USA

*Members of HiTOP Utility Workgroup are listed in the Appendix

The Hierarchical Taxonomy of Psychopathology (HiTOP) is a scientific effort to address shortcomings of traditional mental disorder diagnoses, which suffer from arbitrary boundaries between psychopathology and normality, frequent disorder co-occurrence, heterogeneity within disorders, and diagnostic instability. This paper synthesizes evidence on the validity and utility of the thought disorder and detachment spectra of HiTOP. These spectra are composed of symptoms and maladaptive traits currently subsumed within schizophrenia, other psychotic disorders, and schizotypal, paranoid and schizoid personality disorders. Thought disorder ranges from normal reality testing, to maladaptive trait psychoticism, to hallucinations and delusions. Detachment ranges from introversion, to maladaptive detachment, to blunted affect and avolition. Extensive evidence supports the validity of thought disorder and detachment spectra, as each spectrum reflects common genetics, environmental risk factors, childhood antecedents, cognitive abnormalities, neural alterations, biomarkers, and treatment response. Some of these characteristics are specific to one spectrum and others are shared, suggesting the existence of an overarching psychosis superspectrum. Further research is needed to extend this model, such as clarifying whether mania and dissociation belong to thought disorder, and explicating processes that drive development of the spectra and their subdimensions. Compared to traditional diagnoses, the thought disorder and detachment spectra demonstrated substantially improved utility: greater reliability, larger explanatory and predictive power, and higher acceptability to clinicians. Validated measures are available to implement the system in practice. The more informative, reliable and valid characterization of psychosis-related psychopathology offered by HiTOP can make diagnosis more useful for research and clinical care.

Key words: HiTOP, psychosis, thought disorder, detachment, schizophrenia, psychotic disorders, personality disorders, psychoticism, introversion, clinical utility

(World Psychiatry 2020;19:151–172)

The Hierarchical Taxonomy of Psychopathology (HiTOP) consortium was formed by psychiatric nosologists to integrate evidence from studies on the organization of psychopathology and outline a system based on these data¹. This effort is motivated by shortcomings of traditional taxonomies: arbitrary boundaries between psychopathology and normality, diagnostic instability, heterogeneity within disorders, frequent disorder co-occurrence, and inability to account for subthreshold cases. The HiTOP system addresses these problems by: a) defining psychopathology in terms of dimensions of psychological function that range from normal to abnormal, b) identifying dimensions based on observed covariation among signs, symptoms and maladaptive behaviors, and c) combining these primary dimensions into larger spectra.

The dimensional approach resolves the issue of arbitrary boundaries and diagnostic instability, as evidenced by the high test-retest reliability of dimensional psychopathology constructs²⁻⁵. Also, no patients are excluded from the system, because even individuals with subthreshold symptoms or unusual symptom profiles can be characterized on a set of dimensions. The HiTOP model reduces heterogeneity within constructs by grouping related symptoms together and assigning unrelated symptoms to different dimensions⁶⁻⁹. Comorbidity is recognized in this system through assignment of related conditions to the same spectrum.

The hierarchical organization allows for a flexible description of a patient in terms of broad spectra or narrow subdimensions, depending on the desired degree of specificity.

The HiTOP system currently includes six higher-order spectra: internalizing, somatoform, disinhibited externalizing, antagonistic externalizing, thought disorder, and detachment¹. These major dimensions of psychopathology reflect individual differences in a given domain across the entire population. Spectra can be combined into larger superspectra: emotional dysfunction (internalizing and somatoform), externalizing (disinhibited and antagonistic), and psychosis (thought disorder and detachment)¹⁰⁻¹⁴. Above the superspectra sits the general psychopathology or p factor, a dimension that contains features common to all mental disorders^{15,16}.

The HiTOP system was derived from a large body of structural research^{1,17,18}, but its external validity and utility are less established, as previous reviews of these topics had limited scope¹⁹⁻²¹. To address this shortcoming, the Utility Workgroup of HiTOP consortium assembled teams of experts to systematically review evidence on validity and utility of the system. Expert reviews were organized according to the three superspectra. The present paper is the first in this series and focuses on the psychosis superspectrum.

This superspectrum encompasses two spectra: thought disorder and detachment. The thought disorder spectrum describes individual differences that range from conventional and uncreative thinking to perception and cognition that are only tenuously based in reality. It includes both positive symptoms and the personality trait of psychoticism, also known as positive schizotypy²²⁻²⁷. The label “thought disorder” aims to capture these diverse elements and is distinct from formal thought disorder (i.e., incoherent thought and discourse), which is one of many symptoms in the spectrum. The detachment spectrum describes individual differences in volition (ranging from energetic pursuit of goals to apathy), sociability (ranging from strong social engagement to disinterest in people), and affective expression (ranging from highly expressive to restricted). This spectrum spans from the personality trait of introversion, to negative schizotypy, to negative symptoms^{22,28-32}.

The spectra include both maladaptive traits and symptoms. These parallel each other but reflect different timescales. Signs and symptoms reflect the current state, problems that may be acute and transient; whereas maladaptive traits capture typical levels of these problems over many years and are fairly chronic^{33,34}. For instance, disorganization symptoms indicate current disturbance in organization or expression of thought and odd behavior, whereas trait peculiarity describes very similar problems but assessed over the lifetime. Indeed, disorganization and peculiarity are closely aligned empirically^{35,36}. Furthermore, maladaptive traits change over time, but gradually and slower than symptoms³⁷⁻³⁹. Moreover, traits cover a broader range of individual differences, spanning from healthy to vulnerable to symptomatic⁴⁰⁻⁴², thus providing useful prognostic and etiologic information to complement symptom-based assessment.

The HiTOP follows a long tradition of models that posited a spectrum spanning from normality to personality pathology to schizophrenia⁴³⁻⁴⁵ and elaborates on them using modern statistical modeling techniques and new evidence. It also builds on the idea of an extended psychosis phenotype, a transdiagnostic entity that includes subclinical psychotic experiences as well as frank psychosis⁴⁶⁻⁴⁹. The thought disorder spectrum encompasses this phenotype, and extends it to include trait psychoticism, forming a dimension that spans the entire population. The HiTOP conceptualization of psychotic disorders is also consistent with staging models and clinical high risk approaches⁵⁰⁻⁵³, as HiTOP describes spectra along which people may progress from subthreshold vulnerability to symptoms.

In this paper, we examine the evidence on structural coherence and composition of thought disorder and detachment, and consider the validity and utility of these spectra.

STRUCTURAL EVIDENCE

Composition of major dimensions

The psychosis superspectrum emerges in research on the structure of psychiatric diagnoses¹¹ and of maladaptive per-

sonality traits⁵⁴. It is well-documented as a non-affective dimension of psychosis that encompasses positive and negative symptoms^{6-8,55}. This union of positive and negative symptoms or corresponding maladaptive traits has long been recognized clinically in diagnoses of schizophrenia and schizotypal personality disorder. Indeed, these diagnoses were found to define a dimension distinct from the emotional dysfunction and externalizing superspectra⁵⁶⁻⁶², as summarized in Table 1.

The thought disorder spectrum has been observed in many studies, which defined it primarily by positive symptoms or psychotic experiences^{26,63-66}. Moreover, studies of personality pathology consistently find the corresponding psychoticism dimension⁶⁷⁻⁷¹. The detachment spectrum has been reported in multiple studies of mental disorders^{11,26,62,71-73}. It emerged in research on psychosis as a distinct dimension of negative symptoms^{7,8,30,55,74,75}. Furthermore, detachment has been replicated several times in studies of maladaptive traits⁶⁷⁻⁷⁰, and its healthy range – introversion – is extensively documented^{32,71,76-78}.

Overall, structural studies suggest that schizophrenia, schizotypal disorder, schizoaffective disorder, and schizotypal and paranoid personality disorders reflect elevations on both thought disorder and detachment spectra (Table 1). Other psychotic disorders are linked specifically to the thought disorder spectrum, whereas schizoid and avoidant personality disorders are linked solely to detachment.

Several studies considered obsessive-compulsive disorder and, although some linked it to the psychosis superspectrum^{60,63}, the majority found that it falls within the emotional dysfunction superspectrum^{26,57,58,62,66}. Two studies placed dependent personality disorder on detachment^{62,73}, but meta-analyses of personality disorders and maladaptive traits located dependent personality disorder on internalizing^{70,79,80}. One study linked dysthymic disorder to detachment⁷³, but this is inconsistent with extensive evidence placing depressive disorders on internalizing¹. Consequently, these three disorders and their symptoms will not be considered here.

Dissociative disorders were linked to the thought disorder spectrum in only one study⁶³. However, a substantial literature has documented close ties of dissociative disorders with psychotic disorders and psychoticism⁸¹⁻⁸³. These studies provided evidence of comorbidity, symptom overlap, and common risk factors that support the placement of dissociation within the thought disorder spectrum. In research on the structure of personality pathology, dissociation symptoms have been placed on psychoticism^{84,85}. Hence, we assigned dissociation to thought disorder on a provisional basis, pending further structural research.

Bipolar I disorder was linked to thought disorder in three studies^{56,58,60} and to internalizing in one⁶¹. Several other studies reported an association between mania and internalizing, but did not examine an association between mania and thought disorder⁸⁶⁻⁸⁹. We provisionally included mania in thought disorder, but it remains uncertain whether mania is better placed on internalizing, blends features of both spectra, or forms a dimension distinct from them.

Table 1 Higher-order structures that included psychotic disorders or schizotypal personality disorder in interview-based studies

Sample size	Sample type	Schizophrenia	Schizotypal PD	Psychosis, psychotic experiences			Bipolar I	Paranoid PD	Schizoid PD	Avoidant PD	Dependent PD	Dysthymic disorder	Dissociative disorder	OCD
				+	-	0/0								
Psychosis superspectrum														
Wolf et al ⁶¹	205	Inpatient	+			-								
Markon et al ⁶²	8,405	Community	+	+	+		+	+	-					-
Kotov et al ⁵⁸	2,900	Outpatient	+	+	+		+	+						-
Kotov et al ⁵⁷	469	Inpatient	+	+	+		+	+						-
Keyes et al ⁵⁶	34,653	Community	+	+	+		+	+	+					
Caspi et al ⁶⁰	1,000	Community	+			+								+
Shanmugan et al ⁵⁹	9,498	Community youth	+			+								
Total	57,130		4/4	4/4	3/3	3/4	3/3	3/3	1/2	0/0	0/0	0/0	0/0	1/4
Thought disorder spectrum														
Chmielewski ⁶³	381	Outpatient	+			+							+	+
Wright et al ⁶⁶	8,841	Community				+								-
Wright & Simms ²⁶	628	Outpatient	+	+	+		-							-
Schaefer et al ⁶⁵	2,232	Community adolescents				+								
de Jonge et al ⁶⁴	15,499	Community				+								
Total	27,581		0/0	2/2	5/5	0/0	0/1	0/0	0/0	0/0	0/0	0/0	1/1	1/3
Detachment spectrum														
Markon et al ⁶²	8,405	Community							+		+			
Roysamb et al ⁷³	2,794	Community						+	+		+		+	
Forbes et al ¹¹	2,900	Outpatient		+				+	+					
Wright & Simms ²⁶	628	Outpatient		-				+	-					
Total	14,727		0/0	1/2	0/0	0/0	0/0	3/3	3/4	2/2	1/1	0/0	0/0	0/0

PD – personality disorder, OCD – obsessive-compulsive disorder

Role of maladaptive traits

Psychoticism and detachment traits emerged from research on personality pathology, and are included in the DSM-5 alternative model of personality disorders. These dimensions were also found in research on schizotypy, a personality vulnerability to psychotic disorders, which identified distinct positive and negative schizotypy dimensions⁹⁰. Similar dimensions emerged in research on clinical high risk for psychosis, which described positive and negative risk syndromes⁹¹. Positive schizotypy and positive risk syndrome were found to map onto psychoticism, and negative schizotypy and negative risk syndrome onto detachment^{92,93}.

Psychoticism shows clear links to schizotypal personality disorder, dissociation, and psychotic disorders^{23,26,85,94,95}. Detachment has a specific association with schizoid personality disorder, as well as weaker links to avoidant and schizotypal personality disorders^{23,26,80,94,95}. Both traits are tightly linked to schizophrenia^{24,96}. Overall, cross-sectional data suggest that these traits underpin thought disorder and detachment spectra.

These relationships are further underscored by evidence that psychoticism and detachment predict first onset of psychosis and negative symptoms^{41,97,98}, consistent with the view that these traits are precursors to symptoms⁴³. Psychosis onset is predicted more by psychoticism than detachment, and detachment can be considered a vulnerability trait for negative symptoms and schizophrenia⁹⁸. These findings are consistent with high rates of future schizophrenia onset in treatment-seeking samples with schizotypal personality disorder^{99,100}.

Detachment is aligned with introversion and can be considered its more extreme and maladaptive expression^{32,78,101}. In psychotic disorders, positive symptoms were found to align with psychoticism, and negative symptoms with detachment and introversion^{22,28,29,41,102,103}. Thus, symptoms and traits jointly define HiTOP spectra. Some theories of relations between personality and psychotic disorders hypothesized a latent discontinuity, with risk of psychosis limited to a qualitatively distinct subgroup^{43,104}. Studies of this question produced mixed results, and further research is needed to determine whether any discontinuities exist in the psychosis superspectrum^{105,106}.

Overall model

Subdimensions have been consistently identified within the spectra. Thought disorder symptoms can be decomposed into reality distortion (hallucinations and delusions) and disorganization (formal thought disorder and bizarre behavior) dimensions¹⁰⁷⁻¹⁰⁹. Dissociation and mania can be added as provisional dimensions^{56,58,60,63,83}. The spectrum also includes facets of psychoticism trait: peculiarity (odd appearance, speech and behavior), unusual beliefs (unfounded or magical), unusual experiences (perceptual distortions, depersonalization and derealization), and fantasy proneness (vivid imagination and tendency to become engrossed in inner experiences)^{25,68,78,110}.

Detachment symptoms include inexpressivity and avolition dimensions^{7,111-113}. Trait facets of detachment comprise emotional detachment (difficulties in the experience, description and expression of feelings), anhedonia (deficits in positive emotions and energy), social withdrawal (avoidance of interpersonal interactions due to disinterest), and romantic disinterest (lack of interest in sex and intimacy)^{25,68,78}. Further subdivisions are possible^{74,114,115}, but are not yet established.

The overall model of major dimensions and their components is summarized in Figure 1. It extends the current HiTOP model¹ in several respects based on additional evidence. DSM-5 diagnoses are not included in HiTOP, but they are comprised of the same features (signs, symptoms and traits). Consequently, spectra can be observed in patterns of comorbidity among disorders, thus helping to define these major dimensions of HiTOP. In the present paper, we focus on validity and utility of thought disorder and detachment spectra, although with the understanding that they contain multiple trait and symptom subdimensions.

VALIDITY EVIDENCE

The HiTOP Utility Workgroup examined validity of thought disorder and detachment spectra against nine criteria: behavior genetics, molecular genetics, environmental risk factors, cognitive and emotional processing abnormalities, neural substrates, biomarkers, childhood temperament antecedents, illness course, and treatment response.

These validators are based on the eleven criteria outlined by the American Psychiatric Association's Diagnostic Spectra Study Group for the meta-structure project, the goal of which was to identify coherent clusters of mental disorders¹¹⁶. The meta-structure project criteria were an extension of the validators proposed by Robins and Guze¹¹⁷. Among the eleven criteria, we did not consider "comorbidity" and "symptom similarity", as these are ensured in derivation of the HiTOP model. Indeed, the spectra are defined by disorder and symptom co-occurrence.

We sought to determine whether thought disorder and detachment spectra are coherent on each validator; that is, if psychopathology included in the spectrum has similar associations with the criterion. We examined literatures on symptom dimensions and traits included in the two spectra. Related disorders were considered also, as existing validity research largely focused on diagnostic groups. We found that data on some conditions (e.g., dissociation) are very limited, and we do not discuss them in this validity section.

Behavior genetic evidence

Evidence for a genetically coherent psychosis superspectrum was originally observed in family studies. This research found that relatives of people with schizophrenia have highly increased rates of non-affective psychoses, schizoaffective disorder, schizotypal and paranoid personality disorders, as well as schizopre-




Figure 1 Dimensions within the Hierarchical Taxonomy of Psychopathology (HiTOP) psychosis superspectrum. PD - personality disorder

nia¹¹⁸. Twin research identified a similar genetic factor common to schizotypal, schizoid and paranoid personality disorders¹¹⁹.

Evidence for the thought disorder spectrum is even more compelling. Schizophrenia, bipolar I disorder, and schizoaffective disorder have shown high level of genetic overlap across studies that used family, adoption and twin designs¹²⁰⁻¹²³. This pattern supports the genetic coherence of the thought disorder spectrum. Moreover, family data suggest that this spectrum is distinct from genetic liabilities to internalizing and externalizing problems¹²³. Importantly, twin modeling revealed that genetic risk for thought disorder is continuous, such that clinical and subclinical levels of the spectrum reflect the same genetic liability¹²⁴. Also, directly measured psychoticism was found to be substantially heritable^{125,126}.

The detachment spectrum has been linked to schizophrenia in family studies. This research established that the detachment trait is elevated in relatives of people with schizophrenia compared to relatives of healthy probands or probands with mood disorders, indicating a specific connection between detachment and schizophrenia¹²⁷. Moreover, schizophrenia showed stronger familial associations with detachment than with psychoticism¹²⁷.

Twin studies supported the genetic coherence of the detachment spectrum. They identified a genetic factor common to schizoid and avoidant personality disorders^{128,129}, and potentially to schizotypal personality disorder and dysthymic disorder as well¹²⁸. The genetic detachment factor also emerged in twin studies of maladaptive traits¹²⁹. Furthermore, a twin study of nor-

mal and maladaptive personality found a genetic factor defined by detachment, schizoid and avoidant personality disorders, as well as introversion (and also low openness)¹³⁰. This factor was distinct from genetic liabilities to other forms of personality pathology. Also, directly measured detachment shows considerable heritability^{125,126}.

Overall, this research provided clear evidence of two coherent and distinct genetic factors – aligned with psychoticism and detachment – that underpin the proposed psychosis superspectrum. Moreover, the superspectrum itself is highly heritable, with 73% of variance due to genetic influences¹³¹.

Molecular genetics

Molecular genetic research strongly supports the genetic coherence of the thought disorder spectrum. Genome-wide association studies (GWAS) of schizophrenia and bipolar disorder found that many common genetic variants, each with a small effect size, contribute to risk for both conditions¹³²⁻¹³⁴. Indeed, the genetic correlation between schizophrenia and bipolar disorder is very high ($rg = .70$)^{132,135}. This genetic overlap is further confirmed by correlation between their polygenic risk scores^{136,137}. Notably, bipolar I disorder relates more strongly to schizophrenia than to depression ($rg = .71$ vs. $.30$), whereas the opposite is true for bipolar II disorder ($rg = .51$ vs. $.69$)¹³². Overall, molecular genetic evidence indicates a special connection between mania

and thought disorder. Reality distortion – including subthreshold symptoms – and disorganization were associated with the genetic risk for schizophrenia, but these effects were modest and not specific¹³⁸⁻¹⁴⁰.

The genetic coherence of the detachment spectrum has not been studied, but genetic links between detachment and thought disorder dimensions have been documented, which supports the psychosis superspectrum. Schizophrenia polygenic risk score was found to predict negative symptoms both in patients and in the general population¹⁴⁰⁻¹⁴³. Also, anhedonia and low sociability demonstrated moderate genetic correlations with schizophrenia^{144,145}.

Beyond common genetic variants, approximately 2-3% of schizophrenia patients have rare variants with substantial effect on the risk for the disorder, such as copy number variants (CNVs)¹⁴⁶. CNVs have not been consistently implicated in risk for the psychosis superspectrum aside from schizophrenia. However, one study found elevated burden of CNVs in schizoaffective disorder¹⁴⁷ and another found it in individuals with psychotic experiences¹³⁸.

In sum, molecular genetic research supports the coherence of the thought disorder spectrum and the psychosis superspectrum. Bipolar I disorder has been clearly linked to thought disorder on the genetic level. However, the genetic structure of detachment and lower-order dimensions in both spectra remain to be explicated.

Environmental risk factors

A wide range of environmental risk factors have been identified for schizophrenia and the psychosis superspectrum broadly¹⁴⁸. We focus here on the most replicated effects.

Ethnic minorities and migrants experience high rates of non-affective and affective psychotic disorders¹⁴⁹⁻¹⁵³. In the general population, ethnic minority status was associated with elevated psychoticism^{48,154}. In patients, minority status was correlated with more severe reality distortion, disorganization, and negative symptoms, although this last effect is weaker and less consistent^{8,155-157}. Multiple processes may explain effect of minority status, such as high social adversity, but are not yet fully understood¹⁵³.

The incidence of psychotic disorders is considerably higher in urban than rural areas^{158,159}. In patients with first-episode psychosis, urbanicity was associated with more severe reality distortion and disorganization symptoms¹⁵⁶. In the general population, it was associated with elevated psychoticism¹⁶⁰⁻¹⁶². Links between urbanicity and detachment have not been studied. The effect of urbanicity on psychosis is unlikely to be explained by methodologic confounds, such as social drift, but it is uncertain which of the many exposures common in urban environments explain elevated risk¹⁵⁸. Importantly, the effect appears not to hold in low- and middle-income countries, where urbanicity may index greater access to resources¹⁶³.

Childhood adversity and trauma is a potent risk factor for non-affective and affective psychotic disorders^{164,165}. This association was observed at all levels of thought disorder, from psychoticism to symptoms to diagnosis¹⁶⁶. Childhood adversity is also a risk factor for bipolar I disorder¹⁶⁷. Childhood adversity is clearly

linked to reality distortion symptoms, while its association with negative symptoms is less consistent and understudied, and data on disorganization are lacking¹⁶⁸. With regard to traits, childhood adversity is consistently associated with psychoticism, and preliminary evidence supports a link to detachment^{169,170}.

Cannabis use was found to predict onset of psychotic symptoms and psychotic disorders¹⁷¹. In the general population, it was associated with both elevated psychoticism and detachment, although the latter effect was weaker^{48,172-174}. In patients, cannabis use was associated with more severe reality distortion symptoms and was not consistently linked to other symptoms¹⁷⁵⁻¹⁷⁹.

Overall, these data indicate common risk factors for each spectrum. Ethnic minority status and cannabis use were linked to both detachment and thought disorder spectra, especially to the latter. Urbanicity and childhood adversity were linked more specifically to the thought disorder spectrum.

Cognitive and emotional processing abnormalities

In schizophrenia, schizoaffective disorder, bipolar I disorder, and schizotypal personality disorder, cognitive deficits were documented in all domains: sensorimotor, attention, learning and memory, executive functions, language, and social cognition¹⁸⁰⁻¹⁸⁴. These deficits were most pronounced in schizophrenia, but the other disorders showed a similar, although less extreme, profile of cognitive impairment¹⁸⁵⁻¹⁸⁸. With regard to dimensions, negative and disorganized symptoms were linked to all aforementioned deficits, whereas reality distortion was essentially unrelated to cognitive impairment¹⁸⁹⁻¹⁹¹. Similarly, among maladaptive traits, detachment showed the strongest association with a range of cognitive deficits¹⁹²⁻¹⁹⁴. The reported effects were weaker for traits than for symptoms, likely because nearly all personality studies were performed in non-clinical populations with a limited range of psychopathology.

Schizophrenia, schizoaffective disorder, and schizotypal personality disorder also showed deficits in ability to anticipate and seek pleasurable experiences^{31,182}. Behavioral deficits were documented in reward processing tasks including delay discounting, reinforcement learning, and emotion-based decision making¹⁹⁵⁻¹⁹⁹. These effects were specific to detachment and largely unrelated to thought disorder³¹. In contrast, mania was associated with hypersensitivity to rewards^{200,201}.

Overall, research consistently indicates that cognitive deficits are linked to detachment and disorganization, reward processing deficits are specific to detachment, reward hypersensitivity is specific to mania, and none are clearly related to reality distortion. HiTOP conceptualization of psychopathology can help to isolate associations with cognition that are obscured in heterogeneous diagnoses.

Neural substrates: neuroimaging

Neural correlates of the psychosis superspectrum have been identified using various imaging modalities, and the number of

potential substrates is very large. Here we focus on the most robust findings that were examined across multiple conditions. We discuss the thought disorder spectrum and then the detachment spectrum.

The thought disorder spectrum is associated with structural deficits in numerous brain regions¹⁸². The most replicated finding is smaller hippocampal volume in schizophrenia, schizoaffective disorder, bipolar disorder, and schizotypal personality disorder²⁰²⁻²⁰⁵. This was also observed in relatives of people with schizophrenia²⁰⁶. Furthermore, smaller hippocampal volume was associated with severity of reality distortion symptoms²⁰⁵. Of note, other volumetric differences have been linked to multiple disorders in the spectrum, but research on them is more limited^{203,207-210}.

Structural connectivity abnormalities were reported throughout the thought disorder spectrum. Small splenium of the corpus callosum was found in patients with schizophrenia, schizoaffective disorder, and psychotic bipolar disorder, as well as in their relatives²¹¹. This indicates weak connectivity among multiple brain regions, including the hippocampus. Moreover, smaller splenium was associated with worse reality distortion symptoms²¹¹. Studies using fractional anisotropy found that low white matter integrity in the genu of the corpus callosum and in the posterior cingulum fiber bundle are present in both schizophrenia and bipolar disorder, as further evidence of common abnormalities in structural connectivity²¹².

Functional connectivity alterations were observed in thought disorder as well. The most replicated finding is hypoconnectivity of multiple brain networks in schizophrenia, schizoaffective disorder, and bipolar disorder²¹³⁻²¹⁵. Connectivity patterns differ across conditions, but show substantial overlap, especially hypoconnectivity within the default mode network and cingulo-opercular network. This hypoconnectivity was found across psychotic disorders and in people with psychotic experiences²¹⁶⁻²¹⁸. Similarly, poor efficiency in the connectivity of the cingulo-opercular network was observed across psychotic disorders²¹⁹ and was associated with psychoticism in the general population²¹⁸.

The detachment spectrum has been studied less extensively, but a few promising findings have emerged. A large study not only found a widespread cortical thinning in schizophrenia, but also linked it to negative symptoms, whereas correlations between positive symptoms and cortical thickness were much more limited²⁰⁸. Also, negative symptoms were associated with smaller volume of left caudate nucleus, supporting involvement of the ventral striatum dysfunction in detachment²²⁰.

Functional magnetic resonance imaging supported this interpretation, revealing bilateral hypoactivation of the ventral striatum during potential reward anticipation in schizophrenia, other psychotic disorders, and clinical high risk samples²²¹. Importantly, this hypoactivation was associated with negative and not positive symptoms. These findings are consistent with the role that the ventral striatum plays in motivation and reward processing^{222,223}, in line with emotion deficits described earlier.

With regard to connectivity, negative symptoms were associated with low white matter integrity in many brain regions, including the corpus callosum²²⁴, and with hypoconnectivity

within the default mode network²¹⁶. However, connectivity research is fairly preliminary, and detachment traits and related personality disorders have not been studied.

In addition, abnormal activation patterns within the dorsolateral prefrontal cortex and connected executive control regions during working memory tasks were consistently found in schizophrenia and clinical high risk states^{225,226}. Moreover, these abnormalities were associated with the psychosis superspectrum in the general population²²⁷. Some evidence suggests that this association is with detachment rather than thought disorder, consistent with behavioral data on working memory performance and negative symptoms^{190,227,228}. However, specificity remains uncertain, and abnormal activations during working memory may be a marker of the overarching superspectrum.

Neural substrates: neurophysiology

Neurophysiological measures have provided further understanding of neural processes underpinning the superspectrum. Deficits in basic inhibitory processes have been documented in schizophrenia, schizotypal personality disorder, and bipolar disorder^{182,229,230}. These processes include sensory gating (P50 amplitude), prepulse inhibition, and antisaccade eye movement. They suggest poor selective attention and inhibition, resulting in sensory and cognitive overload, which can contribute to psychoticism and positive symptoms²³⁰.

Electroencephalography probes neural dysfunction more directly. Abnormalities in P300 amplitude and latency as well as mismatch negativity have been established in schizophrenia, clinical high risk states, schizotypal personality disorder, and bipolar disorder^{182,192,231-234}. This pattern suggests that P300 and mismatch negativity track thought disorder, but direct evidence of specificity is limited, and they may prove to be markers of the general psychosis superspectrum.

A relatively new marker is error-related negativity, a key measure of early performance monitoring associated with function of the anterior cingulate²³⁵. This measure is blunted across psychotic disorders as well as in schizotypal personality disorder and clinical high risk groups²³⁶. This blunting appears to be specific to detachment rather than thought disorder^{237,238}.

Biomarkers

Blood-based measures are emerging as potential biomarkers for the psychosis superspectrum. Metabolic dysregulations – such as high glucose and triglyceride levels – can be found in both schizophrenia and bipolar disorder^{239,240}, but they are in part related to the impact of some antipsychotic medications. Pro-inflammatory markers – including interleukin (IL)-6, tumor necrosis factor (TNF)- α , IL1-RA, and sIL-2R – were found to be upregulated both in schizophrenia and bipolar disorder²⁴¹, but this profile is not specific, as depression and other mental disorders show similar abnormalities^{241,242}.

Overall, proteomics research identified 77 proteins altered in

both schizophrenia and bipolar disorder, and only 21 of them were also altered in depression²⁴³. Many of these effects were observed only in a single study. However, alterations in brain-derived neurotrophic factor (BDNF) have been consistently replicated^{244,245}. This is a neurotrophin that modulates neuronal development and plasticity, and its blood levels have been found to be decreased in both schizophrenia and bipolar disorder.

Gene expression has been studied in postmortem brains, and transcriptomic profiles of schizophrenia and bipolar disorder have been found to be very similar²⁴⁶⁻²⁴⁸. The largest study to date reported that cortical transcriptomic profiles of schizophrenia and bipolar disorder are much more similar to each other ($r_s = .70$) than to profiles of major depressive disorder, alcohol use disorder, and autism ($r_s = -.06$ to $.43$)²⁴⁹. The common thought disorder transcriptomic profile includes alterations in multiple pathways, such as genes controlling immune function^{247,249,250}.

Gene expression in the brain is not a practical biomarker, but expression in the peripheral blood tends to mirror expression in the brain²⁵¹. Indeed, blood transcriptomic profiles of schizophrenia and bipolar disorder were found to be similar and include altered expression of immune system genes^{252,253}. Relations between gene expression and symptom dimensions are understudied, but preliminary evidence suggests that altered expression of immune genes is specific to psychoticism, whereas expression of mitochondrial genes is associated with detachment²⁵³. Analyses of DNA methylation in blood revealed similar profiles in schizophrenia and bipolar disorder²⁵⁴, but findings differed across studies and were confounded by methodological differences, so should be considered preliminary.

Overall, studies of immune function, proteomics and transcriptomics suggest that schizophrenia and bipolar disorder share a biological signature. This signature may be common across the thought disorder spectrum. However, conclusions have been moderated by methodological limitations of existing studies, and other disorders and dimensions relevant to the psychosis superspectrum are understudied.

Childhood temperament antecedents

Longitudinal data on links between childhood temperament and adult psychosis superspectrum are very limited. A few studies assessed psychoticism in childhood – using informant reports – and found that it predicted self-reported psychoticism in adolescence and adulthood²⁵⁵⁻²⁵⁷. In youths, both psychoticism and detachment were found to predict future onset of psychotic disorders as well as of schizotypal and schizoid personality disorders, with some evidence that psychoticism is a risk factor primarily for psychotic symptoms and detachment for negative symptoms^{36,41,97,98,258,259}.

This evidence suggests that the psychosis superspectrum has roots in childhood psychoticism and detachment traits, with onset of disorders resulting from progression along the continuum toward greater severity, as has been found for progression

from psychotic experiences to disorder²⁶⁰⁻²⁶². However, existing knowledge is limited by reliance on clinical high risk or treatment-seeking samples and lack of data on preschool temperament. Also, the specificity of the observed links is uncertain, as most studies examined only a small set of traits and disorders.

Illness course

Chronic course is a hallmark of schizophrenia, as only a small minority of cases achieve durable recovery²⁶³. We examined whether chronicity characterizes the entire superspectrum. Recovery is typically defined by both symptom remission and good functioning²⁶⁴, so we considered both in turn. The rate of symptom remission in schizophrenia following treatment is approximately 37%, largely due to high chronicity of negative symptoms²⁶⁵. Likewise, schizotypal and avoidant personality disorders show remission rates of 23-47% two years after diagnosis²⁶⁶. In contrast, 84% of first-admission patients with mania achieve remission within a year²⁶⁷.

Functional outcome follows the same pattern. First-episode schizophrenia results in moderate illness severity at follow-up, with a mean Global Assessment of Functioning (GAF) score of 56²⁶⁸. Schizotypal personality disorder has a similar outcome, with a mean GAF score of 53 at two-year follow-up²⁶⁹. In avoidant personality disorder, two-year outcome is somewhat better, with a mean GAF score of 62, indicating mild severity²⁶⁹. Bipolar disorder shows the best outcome, with a mean GAF score of 70 two years after first hospitalization^{270,271}.

Studies that measured the spectra directly found that psychoticism and detachment are impressively stable over time, with 10-year stability correlations of .66 and .82, respectively²⁷². Moreover, psychoticism, trait detachment, and especially negative symptoms are associated with poor functioning and predict worse global outcomes even ten years later^{41,273-275}. Positive symptoms appear to predict worse functioning in the general population²⁶⁰, but not in patients with psychotic disorders, where negative symptoms account for impairment²⁷⁶. This highlights the greater role of detachment than thought disorder in functioning. Overall, the two spectra show high chronicity and so do many conditions related to them, with the notable exception of mania.

Treatment response

The thought disorder spectrum shows a common response to antipsychotics. These medications are efficacious for reality distortion and disorganization symptoms across psychotic disorders²⁷⁷⁻²⁷⁹. Antipsychotics also treat manic episodes²⁸⁰. Moreover, emerging evidence suggests that antipsychotics can reduce psychoticism in patients who do not have frank psychosis²⁸¹. However, antipsychotics are much less efficacious for the detachment spectrum, such as for negative symptoms, and observed benefits may be limited to secondary negative symp-

toms²⁸². Tentative evidence suggests that neuromodulation techniques providing stimulation to specific neural networks can improve negative symptoms²⁸³, but this research is still limited.

The thought disorder spectrum shows a common response to psychotherapy. Cognitive behavioral therapy (CBT) was found to improve positive symptoms compared to treatment-as-usual both at the end of treatment and at follow-up, but it does not outperform other therapies or active control²⁸⁴. Other emerging treatments may be more efficacious. Acceptance and commitment therapy (ACT) and meta-cognitive therapy both have shown moderate beneficial effects for positive symptoms, although no significant effects for negative symptoms²⁸⁴. Functional behavioral assessment-based interventions appear to be effective for disorganization symptoms across disorders²⁸⁵.

The detachment spectrum shows a common response to social skills training, which reduces negative symptoms²⁸⁶⁻²⁸⁹ and detachment traits²⁹⁰. These effects persist after the end of treatment²⁸⁶ and reduce the probability of transitioning from schizotypal personality disorder to psychotic disorder²⁹¹. Cognitive remediation, a behavioral intervention aimed to improve cognitive processes and not targeting symptoms directly, has been nevertheless found to reduce negative symptoms compared to treatment-as-usual, both at the end of treatment and at follow-up²⁹². CBT is efficacious for reducing negative symptoms across psychotic disorders when compared to treatment-as-usual, both at the end of treatment and at follow-up^{284,287}.

Overall, CBT is an efficacious treatment for both spectra and, indeed, many other forms of psychopathology. In contrast, antipsychotics, ACT and meta-cognitive therapy are relatively specific to the thought disorder spectrum, whereas social skills training and cognitive remediation are relatively specific to the detachment spectrum. Social skills training is efficacious for both detachment symptoms and traits, and emerging evidence suggests that antipsychotics may be efficacious for trait psychoticism as well as frank psychosis. Much less is known about treatment for lower-order dimensions, although social skills training may be particularly efficacious for avolition²⁹³, and functional behavioral assessment-based interventions for disorganization²⁸⁵.

Summary of validity evidence

Our review of validity evidence is summarized in Table 2. It indicates both substantial coherence within each spectrum and overlap between spectra, which supports validity of the superspectrum. However, the two spectra show more differences than similarities, with 15 validators specific to thought disorder, six to detachment, and 12 common to both.

Of note, blank cells in Table 2 indicate lack of robust evidence, but not necessarily lack of an effect. So, similarities within and between the spectra may be stronger than they appear now. In particular, research is very limited on schizoid and avoidant personality disorders.

Importantly, many of the validators examined are not specific

to the psychosis superspectrum. For example, childhood adversity, pro-inflammatory markers, and response to CBT have been linked to emotional dysfunction and externalizing superspectra as well^{56,241,242,294,295}.

Mania stood out on several validators. Unlike other conditions in the superspectrum, bipolar I disorder tends to have episodic course, often shows good functioning between episodes, and manifests hypersensitivity to rewards. On the other hand, bipolar I disorder is similar to other conditions in the spectrum on numerous other validators, consistent with the view that mania belongs on the thought disorder spectrum, albeit with certain distinguishing features.

Overall, validity findings agree with the structural evidence. This suggests that the HiTOP characterization of psychotic disorders and related personality disorders can provide an informative guide to researchers and clinicians.

UTILITY EVIDENCE

The HiTOP has been compared to traditional diagnostic approaches with respect to reliability, explanatory power, prognostic value, and clinical utility.

Reliability is an essential requirement for a nosology, as an unreliable diagnosis cannot convey useful information. The DSM-5 field trials found an inter-rater reliability (kappa coefficient) of .46 for schizophrenia, .50 for schizoaffective disorder, and .56 for bipolar I disorder²⁹⁶, which indicates only mediocre agreement between diagnosticians. In these field trials, clinicians also rated positive symptoms as a single item on a 5-point scale, which, despite its brevity, improved reliability to .65²⁹⁷. Patients' self-ratings of psychosis on a dimensional measure were even more reliable, with coefficients ranging from .72 to .79²⁹⁷. This pattern suggests that dimensional scores retain more useful information than categorical ratings, consistent with extensive prior research².

Of note, a field study of ICD-11 reported higher inter-rater reliabilities than DSM-5 field trials, but it used a less stringent design, making high reliability easier to achieve²⁹⁸.

Psychoticism and detachment demonstrated high reliability in patients (McDonald's omega = .87 and .75, respectively)²⁹⁹ and even higher reliability in the general population³⁰⁰. They also showed high short-term stability, with 2-week test-retest correlations ranging from .81 to .89^{301,302}, and impressive long-term reliability, with 17-month test-retest correlations ranging from .62 to .74³⁹. The overall meta-analytic reliability estimates were .81 for thought disorder and .85 for detachment².

In direct comparison, reliability of DSM diagnoses was inferior to HiTOP dimensions, with 2-week stability of .63 for paranoid, .62 for schizoid, .44 for schizotypal, and .63 for avoidant personality disorders, compared to .88 for psychoticism and .89 for detachment³⁰¹. Overall, HiTOP offers >50% improvement in reliability over the DSM in characterizing psychosis-related psychopathology.

Table 2 Validators of the thought disorder and detachment spectra

	Both spectra		Thought disorder spectrum			Detachment spectrum			Summary of specificity	
	Schizophrenia	Schizotypal PD	Positive symptoms, psychotic experiences	Trait psychoticism	Bipolar I	Negative symptoms	Trait detachment	Schizoid PD		Avoidant PD
Genetics										
Family/twin psychoticism	+++			+	+++					T
Family/twin detachment	+++	+					+++	+++	+++	D
Polygenic risk to schizophrenia	+++		+		+++		++			B
Burden of copy number variants	+++		+							T
Environment										
Ethnic minority status	+++		+++	+			++			B
Living in urban environment	+++		+++	+						T
Childhood adversity	+++		+++	+++	++		+	+		T
Heavy cannabis use	++		++	+++			++			B
Cognition/Neurobiology										
Cognitive deficits	+++	++			+++		+++	++		B
Reward processing deficits	+++	++			-		+++			D
Small hippocampal volume	+++	+++	++		+++					T
Low white matter integrity in CC	+++		+		+++		+			T
Functional hypoconnectivity	+++		+++	+	+++		++			B
Hypoactive ventral striatum	++						++			B
Altered activation of executive system	+++		++	+			++			B
Cortical thinning	++						++			D
Inhibitory deficits	+++	+++								T
Blunted P300	+++	++	++							T
Blunted mismatch negativity	+++	++	++		++					T
Blunted error-related negativity	+++	++					+			D

Table 2 Validators of the thought disorder and detachment spectra (*continued*)

	Both spectra		Thought disorder spectrum			Detachment spectrum			Summary of specificity	
	Schizophrenia	Schizotypal PD	Positive symptoms, psychotic experiences	Trait psychoticism		Negative symptoms	Trait detachment	Schizoid PD		Avoidant PD
				Bipolar I						
Biomarkers										
Pro-inflammatory markers	+++					++				T
Reduced BDNF blood levels	++					++				T
Transcriptomic schizophrenia profile	++					++				T
Antecedents/Course										
Psychoticism in childhood/adolescence	+	++	+++		++					T
Detachment in childhood/adolescence	+	++	++					++		B
High chronicity/stability	+++	+		+		---			+	B
Poor functional outcome	+++	+	+	+		--			+	B
Treatment										
Response to antipsychotics	+++	+	+++		+			+++		B
Response to CBT			+++					+++		B
Response to ACT			++							T
Response to meta-cognitive therapy			+++							T
Response to social skills training									+	D
Response to cognitive remediation									+++	D

+: some evidence for effect, ++: some replications; +++: repeatedly replicated finding, -: some evidence for reverse effect, -- -: some replications; - - -: repeatedly replicated reverse effect, T – linked to thought disorder, D – linked to detachment, B – linked to both, CC – corpus callosum, BDNF – brain-derived neurotrophic factor, CBT – cognitive behavioral therapy, ACT – acceptance and commitment therapy

Explanatory and prognostic power is a particularly valuable feature of diagnosis. A meta-analysis found greater validity for dimensional than categorical operationalization of thought disorder and detachment². For thought disorder, the mean validity coefficient (correlation with a validator) was .31 for a category and .42 for a dimension, which indicates a substantial advantage for the latter. For detachment, the advantage was even larger, with mean validity of .32 for a category and .48 for a dimension. However, these estimates were based largely on cross-sectional associations.

A large longitudinal study found the same pattern when comparing ability of personality disorder diagnoses and maladaptive traits included in HiTOP to predict functional and clinical outcomes ten years later³⁰³. The mean predictive power (R^2) was 0.25 for dimensions vs 0.12 for diagnoses, indicating substantial superiority of the HiTOP approach. However, this study considered all maladaptive traits together and all personality disorders together, and did not report results for psychoticism and detachment separately.

Several studies compared specific dimensions included in the psychosis superspectrum to diagnoses of psychotic disorders by analyzing their cross-sectional associations with validators. Dimensions explained more variance in risk factors³⁰⁴, psychosis biotypes derived from neurophysiological markers⁸, cognitive deficits^{305,306}, real-world functioning^{304,305}, and utilization of inpatient services³⁰⁴. In contrast, diagnoses outperformed dimensions only in accounting for illness course and utilization of outpatient services³⁰⁴.

Another study used diagnoses (e.g., schizophrenia and schizotypal personality disorder) to model the psychosis superspectrum, and found that it fully accounted for family risk and illness course over the next ten years, with individual diagnoses contributing no additional variance⁵⁷.

Overall, existing research indicates that the HiTOP characterization of psychotic disorders can explain and predict twice as much variance in validators as the DSM, thus increasing value of diagnosis for research and for clinical prognostication.

Although diagnostic reliability and prognostic power are important for clinical applications, a distinct set of considerations may be classified as clinical utility, i.e., the ability of a diagnostic system or diagnostic feature to facilitate implementation, conceptualization, communication, treatment selection/planning, and outcome improvement³⁰⁷⁻³¹⁰. Existing research relied on practitioner ratings to evaluate utility of a diagnostic system in these domains.

Comparisons of HiTOP and DSM approaches has been largely focused on personality disorders, and global ratings for the system rather than each individual feature. Initial studies asked practitioners to consider vignettes of fictitious cases developed based on the DSM, which confounded results^{311,312}. Recent studies requested that practitioners consider actual patients in their caseload, and dimensional approaches generally received higher ratings than DSM categories across most indices of clinical utility³¹³⁻³¹⁷. Moreover, dimensional measures included in the DSM-5 were rated by 80% of clinicians as moderately to ex-

tremely helpful³¹⁸.

Overall, existing data strongly support clinical utility of the dimensional approach^{319,320}. Nevertheless, it is important to expand studies of clinical utility to include frank psychosis and also compare diagnostic systems on objective criteria, such as fostering better treatment outcomes.

Clinical acceptability of HiTOP is consistent with the aim of the system to formalize and improve existing clinical decision-making practices, as practitioners often rely on presenting signs and symptoms more than on traditional diagnoses³²¹. Limitations on the utility of traditional diagnoses are further evident in clinicians forgoing criteria sets and employing abbreviated approaches in making diagnoses³²²⁻³²⁴, as well as in extensive off-label prescribing³²⁵. HiTOP builds on an established practice of dimensional, symptom-oriented and personality-informed case conceptualization to provide clinicians with both a rigorous framework for this approach and validated brief tools to assess these dimensions.

Application of dimensional measures in clinical practice faces practical challenges, including limited reimbursement for assessment, patient burden, and need for categorical decisions (e.g., to treat or wait)²⁰. In other fields of medicine, these challenges have not precluded a widespread use of dimensional markers, such as testing levels of metabolites in blood or pathogens in cerebrospinal fluid. Indeed, effective strategies have been developed to justify cost, reduce patient burden, and translate these dimensional metrics into clinical decisions^{326,327}.

Perhaps, the most direct evidence of clinical utility is the widespread use of dimensional measures in mental health practice. Indeed, rating scales for psychosis and related symptoms have been part of clinical practice and research for decades, including the Brief Psychiatric Rating Scale (BPRS)³²⁸, the Scale for the Assessment of Negative Symptoms (SANS)³²⁹, the Scale for Assessment of Positive Symptoms (SAPS)³³⁰, and the Positive and Negative Syndrome Scale (PANSS)³³¹. They have proven clinical acceptability and are required in clinical trials for psychotic disorders³³².

Moreover, programs that treat patients with clinically high risk for psychosis or attenuated psychosis syndrome routinely utilize dimensional symptom measures, especially the Scale of Prodromal Symptoms (SOPS)⁹¹, which is extensively validated and used worldwide³³³.

Structural studies identified subscales in each of these measures that align with the HiTOP model^{7,91,114,334-337}. Indeed, components of the model were informed by this research.

It is notable that diagnostic manuals now recognize the need for a dimensional characterization of psychosis and related symptoms. The DSM-5 introduced eight dimensional ratings that capture reality distortion (hallucinations and delusions), disorganization (disorganized speech and abnormal psychomotor behavior), negative symptoms (restricted expression and avolition), and mania (manic mood), as well as depression and impaired cognition⁷⁴. The ICD-11 included six dimensional symptom-based qualifiers for psychotic disorders: positive, negative and mania, as well as depressive, psychomotor/catatonic and cogni-

tive impairment³³⁸. Although these additions are very encouraging, evidence for their clinical utility is currently limited³¹⁸.

MEASUREMENT

Several measures are available to apply HiTOP in research and care for psychosis-related psychopathology. We highlight instruments that have both sound psychometric properties and established clinical cutoffs (e.g., categorize severity of psychopathology or define clinically significant change).

Both the PANSS and SANS/SAPS offer psychometrically sound interviewer-rated scales for thought disorder (specifically, positive symptoms) and detachment (negative symptoms)^{339,340}. Additional subscales were developed in these measures for reality distortion, disorganization, inexpressivity and avolition, among other dimensions^{7,335,337}.

Two new interviews were developed for negative symptoms: the Clinical Assessment Interview for Negative Symptoms (CAINS)¹¹¹ and the Brief Negative Symptom Scale (BNSS)³⁴¹. Both have psychometrically sound subscales for inexpressivity and avolition³⁴².

The SOPS is the measure of choice in populations with sub-threshold symptoms. It includes four subscales that measure reality distortion, disorganization, negative symptoms, and distress. They largely align with the corresponding scales of the PANSS, SANS and SAPS³⁴³, although factor analytic support for the SOPS subscales has been mixed³⁴⁴.

The Achenbach System of Empirically Based Assessment (ASEBA)^{345,346} includes scales for psychoticism (named thought problems) and detachment (withdrawn). They can be rated by self-report or informant report in both children and adults. These scales have been extensively validated.

Clinical cutoffs are available for the SOPS³³³, ASEBA^{345,346}, and spectra-level scales of the PANSS and SANS/SAPS^{339,347}. These measures are ready for both clinical and research use. The component-level scales of the PANSS and SANS/SAPS, as well as the CAINS and BNSS, lack established cutoffs and can be considered research instruments.

Psychoticism and detachment traits can be assessed with high resolution using omnibus measures of personality pathology, such as the Personality Inventory for DSM-5 (PID-5)³⁴⁸ and the Computerized Adaptive Test of Personality Disorder (CAT-PD)⁷⁸. The Community Assessment of Psychic Experiences (CAPE)^{349,350} is a self-report symptom measure, and provides high-resolution assessment of thought disorder and detachment, as well as their subdimensions. These measures are psychometrically sound and have been normed in the general population, and thus can be used clinically to compare a patient's scores to the normal range of functioning. They also assess subdimensions within psychoticism and detachment domains, including all traits in Figure 1⁶⁸.

Other measures of these maladaptive traits are available, but are less comprehensive or lack norms and hence are not discussed here. Finally, the DSM-5 and ICD-11 dimensional symptom rat-

ings have not been sufficiently studied to be recommended fully, but they show considerable promise as screening tools and can help to introduce dimensional assessments to settings where thorough evaluations are infeasible.

IMPLICATIONS

The HiTOP offers a reconceptualization of psychosis and related psychopathology to closer align nosology with data. It aims to advance understanding of these conditions in three respects.

First, it underscores that psychotic disorders reflect influences of two major dimensions of psychopathology which are rather distinct with regard to their phenomenology, etiology, prognostic implications, and treatment response. These thought disorder and detachment spectra also show similarities, consistent with the notion of the overarching psychosis superspectrum.

The two-spectra conceptualization agrees with an established observation that some patients primarily suffer from positive symptoms and some are largely burdened by negative symptoms^{30,351,352}. Furthermore, this model does not consider psychosis a necessary feature and can characterize people with prominent negative symptoms who have never been psychotic. Of note, internalizing (e.g., depression) and externalizing (e.g., substance abuse) problems are classified on other HiTOP spectra, but are common in psychotic disorders. To characterize a patient fully, all six HiTOP spectra have to be considered, as detailed in previous publications^{1,20}.

Second, the HiTOP reinforces the emerging consensus that psychosis is on a continuum with normal functioning, maladaptive traits, and subthreshold symptoms⁴⁶⁻⁴⁹. The model identifies specific trait manifestations of the spectra: psychoticism and detachment. Elevations on these traits often precede onset of psychosis and are valuable as risk factors. Moreover, levels of psychoticism and detachment vary across the general population, making them more informative targets for etiologic research than psychosis, which is a rare and extreme phenomenon. Overall, the dimensional approach helps to understand how psychosis-related problems are distributed in the population, what processes underpin them, and how preventive interventions can be most effective.

Third, the HiTOP further addresses heterogeneity within psychotic disorders by explicating specific trait and symptom dimensions that constitute the thought disorder and detachment spectra (Figure 1). Included dimensions were established to be internally consistent and distinct, but future research may reveal that more need to be added. In particular, catatonia symptoms and cognitive impairments have not been incorporated into the model.

In the psychosis superspectrum, patients can be represented as profiles of elevations on the corresponding 14 specific dimensions, along with the mean score on the two spectra and on the superspectrum. These dimensions capture both current problems (symptoms) and long-standing problems (maladaptive traits). Validated tools are available to assess these scores by in-

interview, self-report and informant report.

The placement of mania and dissociation on the thought disorder spectrum remains provisional. Dissociation has shown many phenotypic similarities to reality distortion and psychoticism, but the evidence was too limited to include it in our review of validity. Further research is needed to resolve its placement. Mania has been studied extensively and exhibited a profile similar, although generally less extreme, to other thought disorder conditions on numerous validators. The exceptions are course and certain neural substrates. It is possible that mania is a distinct manifestation of a common liability to thought disorder and largely shares etiology and treatment response with non-affective psychosis, although it usually is less disabling. This account remains a hypothesis, as existing data are insufficient to test it definitively.

The HiTOP is a static model at present. Its focus is on characterizing dimensions of psychopathology and accurately assessing a person's current standing on each. However, the hierarchical and dimensional conceptualization is very compatible with developmental models, such as the staging model of psychosis that describes how subthreshold problems evolve into chronic psychosis⁵¹⁻⁵³. Once dimensions are identified, the next task is to characterize how patients progress along these dimensions toward greater pathology or improvement.

The understanding of how thought disorder and detachment spectra develop is quite limited at present, although it appears that the core traits are already present in childhood and constitute risk for onset of psychotic disorders. This is consistent with findings for other HiTOP spectra, which received more attention in developmental research³⁵³⁻³⁵⁵. Specifically, vulnerabilities can often be observed in childhood, and future disorders tend to emerge out of related vulnerabilities, whereas it is fairly uncommon for psychopathology to shift from one spectrum to another. It is less clear what processes and exposures drive progression along a spectrum to full-blown disorder, which remains a crucial topic for future research³⁵⁶.

Research implications

The HiTOP model has specific implications for research design, from the sampling, measurement, analytic and conceptual viewpoints.

With regard to sampling, the HiTOP highlights major limitations of case-control studies, which sample people from extreme ends of a dimension. This can maximize statistical power, but has two downsides. First, these analyses exclude people in the middle of the distribution, which makes identified effects not representative of the population. Indeed, this design ignores a sizable proportion of the general population. Second, cases differ from controls in many respects not relevant to the construct of interest, as they are usually recruited from clinical settings, and treatment-seeking is associated with particularly high rates of distress, impairment, comorbidities (including physical ones), and exposure to medication, all of which may confound results.

These limitations of the case-control design are well-known^{357,358}. The HiTOP provides an impetus for an alternative design with population-based sampling (perhaps oversampling for high scores). This design is reasonable, even desirable, given the continuous nature of psychopathology and the availability of measures that capture the full range of its manifestations, from normative to subclinical to severe¹⁹. The population-based strategy can be cost-effective, in that recruitment of cases with first episode psychosis or clinical high risk tends to be slow and costly, whereas high scorers on psychoticism and detachment can be identified rapidly using self-report tools. This design can be further strengthened with follow-up interview-based assessments to evaluate the spectra and their subdimensions with maximum rigor. Another implication is that research on psychotic disorders should not solely focus on reality distortion, but also include participants who are elevated on detachment alone. In general, inclusion criteria for HiTOP-conformant research can be very broad, with the main concern being whether valid assessment can be obtained. Comorbidities and other confounds can be managed statistically provided adequate sample size.

For measurement, HiTOP-conformant measures described earlier promise more reliable and informative assessments than diagnoses. We recommend assessing both maladaptive traits and symptoms, to obtain a comprehensive picture with a modest increase in patient burden, especially if brief and self-administered instruments are used. The spectra can be usually estimated from categorical diagnoses, but it is preferable to measure them directly within HiTOP-conformant instruments, as this maximizes reliability and information obtained³⁵⁹.

Analytically, HiTOP dimensions can be measured directly and analyzed in the whole sample using conventional statistics. If a diagnostic assessment was completed, it may be useful to test the transdiagnostic nature of relationships of interest, such as whether diagnosis moderates the association between a psychoticism scale and a validator²¹⁹. Latent variable modeling is not required for a HiTOP study, but can be informative. For example, it can facilitate secondary analyses of existing data, where HiTOP-conformant measures were not included, by estimating latent dimensions from standard diagnostic and symptom assessments^{7,8,57,59,306}.

A conceptual implication is that conditions included in a given spectrum tend to have many commonalities with regard to etiology, clinical features, and treatment. This aspect of the model can be leveraged in two ways. First, the spectra can be studied directly, as they provide more parsimonious and robust phenotypes than individual conditions. Second, effects found for one condition are expected to generalize across the spectrum. This will not be true in every case and should always be confirmed empirically, but can be considered a strong hypothesis.

On the balance, some effects will be specific to narrow dimensions rather than the general spectrum. The HiTOP provides the framework for identifying specific and general features of psychopathology. This hierarchical arrangement can help to understand the role of risk factors, outcomes and treatments across mental disorders. Specificity of effects is challenging to investigate under traditional systems that include numerous disorders

and lack a robust hierarchical organization. Our review of validity evidence spotlighted many gaps in knowledge of specificity, and the HiTOP offers a framework to addressing them.

Clinical implications

The HiTOP approach has several implications for clinical care. First, HiTOP diagnosis is a profile of relevant psychopathology dimensions, and the patient is conceptualized in terms of deviations from the healthy range. Traditional diagnosis is de-emphasized, but can be assigned in parallel with HiTOP, such as to meet administrative requirements. Indeed, the consortium developed a cross-walk from HiTOP to ICD-10 codes (<https://hitop.unt.edu/clinical-tools/billing-hitop>).

At some point, scores have to be dichotomized to inform categorical clinical decisions. Of note, traditional diagnoses are dichotomous, but the cutoffs are not optimized for any particular clinical action, and reasons for their selection have not been explicit¹⁸. Optimal use requires development of multiple purpose-built cutoffs (e.g., one for initiating treatment with antipsychotics, another for hospitalization), as has been done in medicine for such dimensional variables as blood pressure, cholesterol, or weight³⁶⁰. This research has not been completed in psychiatry yet, but categories based on degree of statistical deviance (e.g., normal, mild, moderate and high severity) are already available for many measures.

Another consideration is that psychopathology dimensions may interact with each other and with other clinical parameters (e.g., age, medical comorbidities) in ways that change treatment indications and even meaning of scores, such as psychosis that emerges in late life in the context of dementia versus in young adulthood. Many of these interactions are well known, but systematic research is limited. The HiTOP model offers a framework for investigating this question.

Second, the HiTOP offers a hierarchical case conceptualization describing both general and specific features of psychopathology. For example, general dimensions (e.g., p factor) can identify high utilizers of care, thus helping to guide public health policy or policies of a given clinic³⁶¹. In addition, a patient's standing on the thought disorder spectrum may suggest that antipsychotics are indicated. Moreover, on the specific level, an elevation on avolition symptoms may suggest social skills training. Importantly, a move to HiTOP case conceptualization does not negate prior research on traditional diagnoses. Information on treatment efficacy for disorders linked to the spectrum is retained and applied to people elevated on this dimension, although it will be important to verify treatment effects in HiTOP-based treatment studies.

Third, dimensional conceptualization of psychopathology emphasizes continuity with healthy functioning, which can facilitate communication with patients and family members, and help to reduce the stigma of psychopathology. Communication among providers may sometimes benefit from a simpler formulation than an exact score that a patient received on a dimension, and categorization can be applied based on the aforementioned

cutoffs. For example, “moderately elevated detachment” could be used instead of listing the specific score.

A salient pragmatic concern is assessment burden on clinics. Many HiTOP assessments have been digitized, so that the questionnaire can be sent to patients for completion at home or in a waiting room, with results scored automatically and provided to clinicians in real time. Importantly, these measures do not aim to replace an intake interview, but to guide clinicians' interviewing, thus improving speed and comprehensiveness of an intake and subsequent monitoring, much like lab tests do in medicine.

FUTURE DIRECTIONS

The proposed HiTOP model of the psychosis superspectrum is based on extensive evidence. Nevertheless, further research is needed to verify assignment of mania and dissociation, as well as to incorporate other dimensions in the model (e.g., cognitive impairment and catatonia). The HiTOP is meant to include all empirical psychopathological entities, whether dimensional or categorical in nature. Only dimensions have been established empirically to date¹⁸. However, latent classes likely exist³⁶², so they need to be identified and added to the psychosis superspectrum alongside dimensions.

Research is also needed on optimal cutoffs for specific clinical decisions. Interactions among dimensions and with other clinical features need to be investigated systematically. It will be particularly important to verify and expand knowledge of treatment efficacy with dimensions as treatment targets. Finally, thought disorder and detachment spectra have been extensively validated, but gaps remain for a number of validators, such as childhood antecedents and biomarkers. Developmental processes, in particular, need more attention. This research can build on the strong base of knowledge and scientific framework provided by HiTOP.

CONCLUSIONS

The HiTOP offers a dimensional and hierarchical conceptualization of psychotic disorders that was derived strictly from data, free of political considerations. It has been extensively validated and already demonstrated considerable utility. Validated measures are available for spectra and their subdimensions for both symptoms and traits.

Further research is needed, but the model is ready for use by scientists and clinicians interested in psychotic disorders. Its application offers to address problems of heterogeneity, comorbidity and low reliability, providing more valid and predictive descriptions of patients.

APPENDIX

Members of HiTOP Utility Workgroup include, in addition to the authors of this paper, Kamran Afzali, Marina A. Bornovalova, Natacha Carragher, David C. Cicero, Christopher C. Conway, Anna R. Docherty, Michael B. First, Eiko I. Fried, Michael N. Hallquist, Kristian E. Markon, Les C. Morey, Stephanie N. Mullins-Sweatt, Kristin Naragon-Gainey, Thomas M. Olino, Praveetha Patalay, Aaron

L. Pincus, Craig Rodriguez-Seijas, Giovanni A. Salum, Alexander J. Shackman, Andrew E. Skodol, Kathryn Tabb, Jennifer L. Tackett, Irwin D. Waldman, Ashley L. Watts, Amanda A. Uliaszek, Johannes Zimmermann and Richard E. Zinbarg.

ACKNOWLEDGEMENTS

Further information on the HiTOP consortium can be found at <http://medicine.stonybrookmedicine.edu/HITOP>. U. Reininghaus is supported by a Heisenberg professorship from the German Research Foundation (grant no. 389624707). R.F. Krueger and D. Watson are joint senior authors of this paper.

REFERENCES

1. Kotov R, Krueger RF, Watson D et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): a dimensional alternative to traditional nosologies. *J Abnorm Psychol* 2017;126:454-77.
2. Markon KE, Chmielewski M, Miller CJ. The reliability and validity of discrete and continuous measures of psychopathology: a quantitative review. *Psychol Bull* 2011;137:856-79.
3. Shankman SA, Funkhouser CJ, Klein DN et al. Reliability and validity of severity dimensions of psychopathology assessed using the Structured Clinical Interview for DSM-5 (SCID). *Int J Methods Psychiatr Res* 2018;27(1).
4. Chmielewski M, Clark LA, Bagby RM et al. Method matters: understanding diagnostic reliability in DSM-IV and DSM-5. *J Abnorm Psychol* 2015;124:764-9.
5. Watson D. Subtypes, specifiers, epicycles, and eccentrics: toward a more parsimonious taxonomy of psychopathology. *Clin Psychol Sci Pract* 2003;10:233-8.
6. Cuesta MJ, Peralta V. Integrating psychopathological dimensions in functional psychoses: a hierarchical approach. *Schizophr Res* 2001;52:215-29.
7. Kotov R, Foti D, Li K et al. Validating dimensions of psychosis symptomatology: neural correlates and 20-year outcomes. *J Abnorm Psychol* 2016;125:1103-19.
8. Reininghaus U, Bohnke JR, Chavez-Baldini U et al. Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). *World Psychiatry* 2019;18:67-76.
9. Ruggero CJ, Kotov R, Watson D et al. Beyond a single index of mania symptoms: structure and validity of subdimensions. *J Affect Disord* 2014;161:8-15.
10. Anderson JL, Sellbom M, Ayeart L et al. Associations between DSM-5 section III personality traits and the Minnesota Multiphasic Personality Inventory 2 - Restructured Form (MMPI-2-RF) scales in a psychiatric patient sample. *Psychol Assess* 2015;27:801-15.
11. Forbes MK, Kotov R, Ruggero CJ et al. Delineating the joint hierarchical structure of clinical and personality disorders in an outpatient psychiatric sample. *Compr Psychiatry* 2017;79:19-30.
12. Krueger RF, Chentsova-Dutton YE, Markon KE et al. A cross-cultural study of the structure of comorbidity among common psychopathological syndromes in the general health care setting. *J Abnorm Psychol* 2003;112:437-47.
13. Krueger RF, Markon KE, Patrick CJ et al. Linking antisocial behavior, substance use, and personality: an integrative quantitative model of the adult externalizing spectrum. *J Abnorm Psychol* 2007;116:645-66.
14. Patrick CJ, Kramer MD, Krueger RF et al. Optimizing efficiency of psychopathology assessment through quantitative modeling: development of a brief form of the Externalizing Spectrum Inventory. *Psychol Assess* 2013;25:1332-48.
15. Caspi A, Moffitt TE. All for one and one for all: mental disorders in one dimension. *Am J Psychiatry* 2018;175:831-44.
16. Lahey BB, Krueger RF, Rathouz PJ et al. A hierarchical causal taxonomy of psychopathology across the life span. *Psychol Bull* 2017;143:142-86.
17. Kotov R, Krueger RF, Watson D. A paradigm shift in psychiatric classification: the Hierarchical Taxonomy Of Psychopathology (HiTOP). *World Psychiatry* 2018;17:24-5.
18. Krueger RF, Kotov R, Watson D et al. Progress in achieving quantitative classification of psychopathology. *World Psychiatry* 2018;17:282-93.
19. Conway CC, Forbes MK, Forbush KT et al. A Hierarchical Taxonomy of Psychopathology can transform mental health research. *Perspect Psychol Sci* 2019;14:419-36.
20. Ruggero CJ, Kotov R, Hopwood CJ et al. Integrating the Hierarchical Taxonomy of Psychopathology (HiTOP) into clinical practice. *J Consult Clin Psychol* 2019;87:1069-84.
21. Waszczuk MA, Eaton NR, Krueger RF et al. Redefining phenotypes to advance psychiatric genetics: implications from hierarchical taxonomy of psychopathology. *J Abnorm Psychol* 2020;129:143-61.
22. Cicero DC, Jonas KG, Li K et al. Common taxonomy of traits and symptoms: linking schizophrenia symptoms, schizotypy, and normal personality. *Schizophr Bull* 2019;45:1336-48.
23. Kwapil TR, Barrantes-Vidal N, Silvia PJ. The dimensional structure of the Wisconsin Schizotypy Scales: factor identification and construct validity. *Schizophr Bull* 2008;34:444-57.
24. Longenecker JM, Krueger RF, Sponheim SR. Personality traits across the psychosis spectrum: a Hierarchical Taxonomy of Psychopathology conceptualization of clinical symptomatology. *Personal Ment Health* 2020;14:88-105.
25. Widiger TA, Crego C. HiTOP thought disorder, DSM-5 psychoticism, and five factor model openness. *J Res Person* 2019;80:72-7.
26. Wright AG, Simms LJ. A metastructural model of mental disorders and pathological personality traits. *Psychol Med* 2015;45:2309-19.
27. Lenzenweger MF. Schizotypy, schizotypic psychopathology and schizophrenia. *World Psychiatry* 2018;17:25-6.
28. Boyette LL, Korver-Nieberg N, Verweij K et al. Associations between the Five-Factor Model personality traits and psychotic experiences in patients with psychotic disorders, their siblings and controls. *Psychiatry Res* 2013;210:491-7.
29. Compton MT, Bakeman R, Alolayan Y et al. Personality domains, duration of untreated psychosis, functioning, and symptom severity in first-episode psychosis. *Schizophr Res* 2015;168:113-9.
30. Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. *Schizophr Bull* 1974;Winter:61-9.
31. Strauss GP, Cohen AS. A transdiagnostic review of negative symptom phenomenology and etiology. *Schizophr Bull* 2017;43:712-9.
32. Suzuki T, Samuel DB, Pahlen S et al. DSM-5 alternative personality disorder model traits as maladaptive extreme variants of the five-factor model: an item-response theory analysis. *J Abnorm Psychol* 2015;124:343-54.
33. Fagerberg T, Soderman E, Petter Gustavsson J et al. Stability of personality traits over a five-year period in Swedish patients with schizophrenia spectrum disorder and non-psychotic individuals: a study using the Swedish universities scales of personality. *BMC Psychiatry* 2018;18:54.
34. Boyette LL, Nederlof J, Meijer C et al. Three year stability of Five-Factor Model personality traits in relation to changes in symptom levels in patients with schizophrenia or related disorders. *Psychiatry Res* 2015;229:539-44.
35. Kerns JG, Becker TM. Communication disturbances, working memory, and emotion in people with elevated disorganized schizotypy. *Schizophr Res* 2008;100:172-80.
36. Raine A. Schizotypal personality: neurodevelopmental and psychosocial trajectories. *Annu Rev Clin Psychol* 2006;2:291-326.
37. Caspi A, Roberts BW, Shiner RL. Personality development: stability and change. *Annu Rev Psychol* 2005;56:453-84.
38. Ferguson CJ. A meta-analysis of normal and disordered personality across the life span. *J Pers Soc Psychol* 2010;98:659-67.
39. Wright AG, Calabrese WR, Rudick MM et al. Stability of the DSM-5 Section III pathological personality traits and their longitudinal associations with psychosocial functioning in personality disordered individuals. *J Abnorm Psychol* 2015;124:199-207.
40. Clark LA. Assessment and diagnosis of personality disorder: perennial issues and an emerging reconceptualization. *Annu Rev Psychol* 2007;58:227-57.
41. Kwapil TR, Gross GM, Silvia PJ et al. Prediction of psychopathology and functional impairment by positive and negative schizotypy in the Chapmans' ten-year longitudinal study. *J Abnorm Psychol* 2013;122:807-15.
42. Widiger TA, Trull TJ. Plate tectonics in the classification of personality disorder: shifting to a dimensional model. *Am Psychol* 2007;62:71-83.
43. Meehl PE. Schizotaxia, schizotypy, schizophrenia. *Am Psychol* 1962;17:827-38.
44. Claridge G, Beech T. Fully and quasi-dimensional constructions of schizotypy. *Schizotypal personality*. New York: Cambridge University Press, 1995:192-216.
45. Kendler KS, McGuire M, Gruenberg AM et al. The Roscommon Family Study. III. Schizophrenia-related personality disorders in relatives. *Arch Gen Psychiatry* 1993;50:781-8.
46. Guloksuz S, van Os J. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. *Psychol Med* 2018;48:229-44.
47. van Os J, Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population. *World Psychiatry* 2016;15:118-24.
48. Linscott RJ, van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in chil-

- dren and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. *Psychol Med* 2013;43:1133-49.
49. van Os J, Linscott RJ, Myin-Germeys I et al. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. *Psychol Med* 2009;39:179-95.
 50. Fusar-Poli P, Borgwardt S, Bechdolf A et al. The psychosis high-risk state: a comprehensive state-of-the-art review. *JAMA Psychiatry* 2013;70:107-20.
 51. McGorry PD, Nelson B. Why we need a transdiagnostic staging approach to emerging psychopathology, early diagnosis, and treatment. *JAMA Psychiatry* 2016;73:191-2.
 52. McGorry PD, Hickie IB, Yung AR et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. *Aust N Z J Psychiatry* 2006;40:616-22.
 53. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. *Schizophr Bull* 1996;22:353-70.
 54. Morey LC, Krueger RF, Skodol AE. The hierarchical structure of clinician ratings of proposed DSM-5 pathological personality traits. *J Abnorm Psychol* 2013;122:836-41.
 55. Russo M, Levine SZ, Demjaha A et al. Association between symptom dimensions and categorical diagnoses of psychosis: a cross-sectional and longitudinal investigation. *Schizophr Bull* 2014;40:111-9.
 56. Keyes KM, Eaton NR, Krueger RF et al. Childhood maltreatment and the structure of common psychiatric disorders. *Br J Psychiatry* 2012;200:107-15.
 57. Kotov R, Chang SW, Fochtmann LJ et al. Schizophrenia in the internalizing-externalizing framework: a third dimension? *Schizophr Bull* 2011;37:1168-78.
 58. Kotov R, Ruggero CJ, Krueger RF et al. New dimensions in the quantitative classification of mental illness. *Arch Gen Psychiatry* 2011;68:1003-11.
 59. Shanmugan S, Wolf DH, Calkins ME et al. Common and dissociable mechanisms of executive system dysfunction across psychiatric disorders in youth. *Am J Psychiatry* 2016;173:517-26.
 60. Caspi A, Houts RM, Belsky DW et al. The p factor: one general psychopathology factor in the structure of psychiatric disorders? *Clin Psychol Sci* 2014;2:119-37.
 61. Wolf AW, Schubert DS, Patterson MB et al. Associations among major psychiatric diagnoses. *J Consult Clin Psychol* 1988;56:292-4.
 62. Markon KE. Modeling psychopathology structure: a symptom-level analysis of Axis I and II disorders. *Psychol Med* 2010;40:273-88.
 63. Chmielewski MS. The structure of common and severe psychopathology: analyses of syndromes and symptoms. PhD Thesis, University of Iowa, 2012.
 64. de Jonge P, Wardenaar KJ, Lim CCW et al. The cross-national structure of mental disorders: results from the World Mental Health Surveys. *Psychol Med* 2018;48:2073-84.
 65. Schaefer JD, Moffitt TE, Arseneault L et al. Adolescent victimization and early-adult psychopathology: approaching causal inference using a longitudinal twin study to rule out noncausal explanations. *Clin Psychol Sci* 2018;6:352-71.
 66. Wright AG, Krueger RF, Hobbs MJ et al. The structure of psychopathology: toward an expanded quantitative empirical model. *J Abnorm Psychol* 2013;122:281-94.
 67. Anderson JL, Sellbom M, Bagby RM et al. On the convergence between PSY-5 domains and PID-5 domains and facets: implications for assessment of DSM-5 personality traits. *Assessment* 2013;20:286-94.
 68. Crego C, Widiger TA. Convergent and discriminant validity of alternative measures of maladaptive personality traits. *Psychol Assess* 2016;28:1561-75.
 69. Krueger RF, Markon KE. The role of the DSM-5 personality trait model in moving toward a quantitative and empirically based approach to classifying personality and psychopathology. *Annu Rev Clin Psychol* 2014;10:477-501.
 70. Somma A, Krueger RF, Markon KE et al. The replicability of the Personality Inventory for DSM-5 domain scale factor structure in U.S. and non-U.S. samples: a quantitative review of the published literature. *Psychol Assess* 2019;31:861-77.
 71. Widiger TA, Sellbom M, Chmielewski M et al. Personality in a hierarchical model of psychopathology. *Clin Psychol Sci* 2019;7:77-92.
 72. Girard JM, Wright AGC, Beeneey JE et al. Interpersonal problems across levels of the psychopathology hierarchy. *Compr Psychiatry* 2017;79:53-69.
 73. Roysamb E, Kendler KS, Tams K et al. The joint structure of DSM-IV Axis I and Axis II disorders. *J Abnorm Psychol* 2011;120:198-209.
 74. Barch DM, Bustillo J, Gaebel W et al. Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. *Schizophr Res* 2013;150:15-20.
 75. Shevlin M, McElroy E, Bentall RP et al. The psychosis continuum: testing a bifactor model of psychosis in a general population sample. *Schizophr Bull* 2017;43:133-41.
 76. Costa PT Jr, McCrae RR. The NEO Inventories as instruments of psychological theory. In: Widiger TA (ed). *The Oxford handbook of the Five Factor Model*. New York: Oxford University Press, 2017:11-37.
 77. John OP, Naumann LP, Soto CJ. Paradigm shift to the integrative Big Five trait taxonomy: history, measurement, and conceptual issues. In: John OP, Robins RW, Pervin LA (eds). *Handbook of personality: theory and research*, 3rd ed. New York: Guilford, 2008:114-58.
 78. Wright AGC, Simms LJ. On the structure of personality disorder traits: conjoint analyses of the CAT-PD, PID-5, and NEO-PI-3 trait models. *Personal Disord* 2014;5:43-54.
 79. O'Connor BP. A search for consensus on the dimensional structure of personality disorders. *J Clin Psychol* 2005;61:323-45.
 80. Samuel DB, Widiger TA. A meta-analytic review of the relationships between the five-factor model and DSM-IV-TR personality disorders: a facet level analysis. *Clin Psychol Rev* 2008;28:1326-42.
 81. Kilcommons AM, Morrison AP. Relationships between trauma and psychosis: an exploration of cognitive and dissociative factors. *Acta Psychiatr Scand* 2005;112:351-9.
 82. Koffel E, Watson D. Unusual sleep experiences, dissociation, and schizotypy: evidence for a common domain. *Clin Psychol Rev* 2009;29:548-59.
 83. Renard SB, Huntjens RJ, Lysaker PH et al. Unique and overlapping symptoms in schizophrenia spectrum and dissociative disorders in relation to models of psychopathology: a systematic review. *Schizophr Bull* 2017;43:108-21.
 84. Ashton MC, Lee K. Recovering the HEXACO personality factors – and psychoticism – from variable sets assessing normal and abnormal personality. *J Individ Differ* (in press).
 85. Ashton MC, Lee K, de Vries RE et al. The maladaptive personality traits of the Personality Inventory for DSM-5 (PID-5) in relation to the HEXACO personality factors and schizotypy/dissociation. *J Pers Disord* 2012;26:641-59.
 86. Blanco C, Wall MM, He JP et al. The space of common psychiatric disorders in adolescents: comorbidity structure and individual latent liabilities. *J Am Acad Child Adolesc Psychiatry* 2015;54:45-52.
 87. Forbush KT, Watson D. The structure of common and uncommon mental disorders. *Psychol Med* 2013;43:97-108.
 88. Kotov R, Perlman G, Gamez W et al. The structure and short-term stability of the emotional disorders: a dimensional approach. *Psychol Med* 2015;45:1687-98.
 89. Watson D, O'Hara MW, Naragon-Gainey K et al. Development and validation of new anxiety and bipolar symptom scales for an expanded version of the IDAS (the IDAS-II). *Assessment* 2012;19:399-420.
 90. Kwapil TR, Barrantes-Vidal N. Schizotypy: looking back and moving forward. *Schizophr Bull* 2015;41(Suppl. 2):S366-73.
 91. Miller TJ, McGlashan TH, Rosen JL et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophr Bull* 2003;29:703-15.
 92. Cicero DC, Martin EA, Becker TM et al. Correspondence between psychometric and clinical high risk for psychosis in an undergraduate population. *Psychol Assess* 2014;26:901-15.
 93. Moorman EL, Samuel DB. Representing schizotypal thinking with dimensional traits: a case for the Five Factor Schizotypal Inventory. *Psychol Assess* 2018;30:19-30.
 94. Hopwood CJ, Thomas KM, Markon KE et al. DSM-5 personality traits and DSM-IV personality disorders. *J Abnorm Psychol* 2012;121:424-32.
 95. Watters CA, Bagby RM, Sellbom M. Meta-analysis to derive an empirically based set of personality facet criteria for the alternative DSM-5 model for personality disorders. *Personal Disord* 2019;10:97-104.
 96. Camisa KM, Bockbrader MA, Lysaker P et al. Personality traits in schizophrenia and related personality disorders. *Psychiatry Res* 2005;133:23-33.
 97. Cannon TD, Yu C, Addington J et al. An individualized risk calculator for research in prodromal psychosis. *Am J Psychiatry* 2016;173:980-8.
 98. Debbané M, Eliez S, Badoud D et al. Developing psychosis and its risk states through the lens of schizotypy. *Schizophr Bull* 2015;41(Suppl. 2):S396-407.
 99. Fluckiger R, Ruhrmann S, Debbané M et al. Psychosis-predictive value of self-reported schizotypy in a clinical high-risk sample. *J Abnorm Psychol* 2016;125:923-32.
 100. Hjorthoj C, Albert N, Nordentoft M. Association of substance use disorders with conversion from schizotypal disorder to schizophrenia. *JAMA Psychiatry* 2018;75:733-9.

101. Crego C, Oltmanns JR, Widiger TA. FFMPD scales: comparisons with the FFM, PID-5, and CAT-PD-SF. *Psychol Assess* 2018;30:62-73.
102. Barrantes-Vidal N, Lewandowski KE, Kwapil TR. Psychopathology, social adjustment and personality correlates of schizotypy clusters in a large nonclinical sample. *Schizophr Res* 2010;122:219-25.
103. Barrantes-Vidal N, Gross GM, Sheinbaum T et al. Positive and negative schizotypy are associated with prodromal and schizophrenia-spectrum symptoms. *Schizophr Res* 2013;145:50-5.
104. Lenzenweger MF. *Schizotypy and schizophrenia: the view from experimental psychopathology*. New York: Guilford, 2010.
105. Grant P, Green MJ, Mason OJ. Models of schizotypy: the importance of conceptual clarity. *Schizophr Bull* 2018;44(Suppl. 2):S556-63.
106. Haslam N, Holland E, Kuppens P. Categories versus dimensions in personality and psychopathology: a quantitative review of taxometric research. *Psychol Med* 2012;42:903-20.
107. Andreasen NC, Arndt S, Alliger R et al. Symptoms of schizophrenia. Methods, meanings, and mechanisms. *Arch Gen Psychiatry* 1995;52:341-51.
108. Grube BS, Bilder RM, Goldman RS. Meta-analysis of symptom factors in schizophrenia. *Schizophr Res* 1998;31:113-20.
109. Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. *Br J Psychiatry* 1987;151:145-51.
110. Bagby RM, Widiger TA. Five Factor Model personality disorder scales: an introduction to a special section on assessment of maladaptive variants of the five factor model. *Psychol Assess* 2018;30:1-9.
111. Kring AM, Gur RE, Blanchard JJ et al. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. *Am J Psychiatry* 2013;170:165-72.
112. Strauss GP, Hong LE, Gold JM et al. Factor structure of the Brief Negative Symptom Scale. *Schizophr Res* 2012;142:96-8.
113. Strauss GP, Horan WP, Kirkpatrick B et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. *J Psychiatr Res* 2013;47:783-90.
114. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. *Schizophr Bull* 2006;32:238-45.
115. Peralta V, Moreno-Izco L, Calvo-Barrena L et al. The low- and higher-order factor structure of symptoms in patients with a first episode of psychosis. *Schizophr Res* 2013;147:116-24.
116. Andrews G, Goldberg DP, Krueger RF et al. Exploring the feasibility of a meta-structure for DSM-V and ICD-11: could it improve utility and validity? *Psychol Med* 2009;39:1993-2000.
117. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. *Am J Psychiatry* 1970;126:983-7.
118. Kendler KS, Gardner CO. The risk for psychiatric disorders in relatives of schizophrenic and control probands: a comparison of three independent studies. *Psychol Med* 1997;27:411-9.
119. Kendler KS, Czajkowski N, Tamsb K et al. Dimensional representations of DSM-IV cluster A personality disorders in a population-based sample of Norwegian twins: a multivariate study. *Psychol Med* 2006;36:1583-91.
120. Cardno AG, Owen MJ. Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder. *Schizophr Bull* 2014;40:504-15.
121. Lichtenstein P, Yip BH, Bjork C et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet* 2009;373:234-9.
122. Klasing U, Trumbetta SL, Gottesman II et al. A Danish twin study of schizophrenia liability: investigation from interviewed twins for genetic links to affective psychoses and for cross-cohort comparisons. *Behav Genet* 2016;46:193-204.
123. Pettersson E, Larsson H, Lichtenstein P. Common psychiatric disorders share the same genetic origin: a multivariate sibling study of the Swedish population. *Mol Psychiatry* 2016;21:717-21.
124. Zavos HM, Freeman D, Haworth CM et al. Consistent etiology of severe, frequent psychotic experiences and milder, less frequent manifestations: a twin study of specific psychotic experiences in adolescence. *JAMA Psychiatry* 2014;71:1049-57.
125. Wright ZE, Pahlen S, Krueger RF. Genetic and environmental influences on Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) maladaptive personality traits and their connections with normative personality traits. *J Abnorm Psychol* 2017;126:416-28.
126. South SC, Krueger RF, Knudsen GP et al. A population based twin study of DSM-5 maladaptive personality domains. *Personal Disord* 2017;8:366-75.
127. Tarbox SI, Pogue-Geile MF. A multivariate perspective on schizotypy and familial association with schizophrenia: a review. *Clin Psychol Rev* 2011;31:1169-82.
128. Kendler KS, Aggen SH, Czajkowski N et al. The structure of genetic and environmental risk factors for DSM-IV personality disorders: a multivariate twin study. *Arch Gen Psychiatry* 2008;65:1438-46.
129. Kendler KS, Aggen SH, Knudsen GP et al. The structure of genetic and environmental risk factors for syndromal and subsyndromal common DSM-IV axis I and all axis II disorders. *Am J Psychiatry* 2011;168:29-39.
130. Kendler KS, Aggen SH, Gillespie N et al. The structure of genetic and environmental influences on normative personality, abnormal personality traits, and personality disorder symptoms. *Psychol Med* 2019;49:1392-9.
131. Hilker R, Helenius D, Fagerlund B, et al. Heritability of schizophrenia and schizophrenia spectrum based on the Nationwide Danish Twin Register. *Biol Psychiatry* 2018;83:492-8.
132. Stahl EA, Breen G, Forstner AJ et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat Genet* 2019;51:793-803.
133. Sullivan PF, Agrawal A, Bulik CM, et al. Psychiatric genomics: an update and an agenda. *Am J Psychiatry* 2018;175:15-27.
134. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 2014;511:421-7.
135. Brainstorm Consortium, Anttila V, Bulik-Sullivan B et al. Analysis of shared heritability in common disorders of the brain. *Science* 2018;360(6395).
136. Docherty AR, Moscati A, Dick D et al. Polygenic prediction of the phenome, across ancestry, in emerging adulthood. *Psychol Med* 2018;48:1814-23.
137. Tesli M, Espeseth T, Bettella F et al. Polygenic risk score and the psychosis continuum model. *Acta Psychiatr Scand* 2014;130:311-7.
138. Legge SE, Jones HJ, Kendall KM et al. Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits. *JAMA Psychiatry* (in press).
139. Martin J, Taylor MJ, Lichtenstein P. Assessing the evidence for shared genetic risks across psychiatric disorders and traits. *Psychol Med* 2018;48:1759-74.
140. Ronald A, Pain O. A systematic review of genome-wide research on psychotic experiences and negative symptom traits: new revelations and implications for psychiatry. *Hum Mol Genet* 2018;27:R136-52.
141. Mistry S, Harrison JR, Smith DJ et al. The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: systematic review. *Schizophr Res* 2018;197:2-8.
142. Pain O, Dudbridge F, Cardno AG et al. Genome-wide analysis of adolescent psychotic-like experiences shows genetic overlap with psychiatric disorders. *Am J Med Genet B Neuropsychiatr Genet* 2018;177:416-25.
143. Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. *Cell* 2018;173:1705-15.e16.
144. Bralten J, Klemann C, Mota N et al. Genetic underpinnings of sociability in the UK Biobank. *bioRxiv* 2019:781195.
145. Ward J, Lyall LM, Bethlehem RAI et al. Novel genome-wide associations for anhedonia, genetic correlation with psychiatric disorders, and polygenic association with brain structure. *Transl Psychiatry* 2019;9:327.
146. Marshall CR, Howrigan DP, Merico D et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet* 2017;49:27-35.
147. Charney AW, Stahl EA, Green EK, et al. Contribution of rare copy number variants to bipolar disorder risk is limited to schizoaffective cases. *Biol Psychiatry* 2019;86:110-9.
148. Radua J, Ramella-Cravaro V, Ioannidis JPA et al. What causes psychosis? An umbrella review of risk and protective factors. *World Psychiatry* 2018;17:49-66.
149. Bourque F, van der Ven E, Malla A. A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. *Psychol Med* 2011;41:897-910.
150. Cantor-Graae E, Selten JP. Schizophrenia and migration: a meta-analysis and review. *Am J Psychiatry* 2005;162:12-24.
151. Kirkbride JB, Errazuriz A, Croudace TJ et al. Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analysis. *PLoS One* 2012;7:e31660.
152. Kirkbride JB, Fearon P, Morgan C et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. *Arch Gen Psychiatry* 2006;63:250-8.
153. Morgan C, Knowles G, Hutchinson G. Migration, ethnicity and psychosis: evidence, models and future directions. *World Psychiatry* 2019;18:247-58.
154. Morgan C, Fisher H, Hutchinson G et al. Ethnicity, social disadvantage and psychotic-like experiences in a healthy population based sample. *Acta Psychiatr Scand* 2009;119:226-35.

155. Perlman G, Kotov R, Fu J et al. Symptoms of psychosis in schizophrenia, schizoaffective disorder, and bipolar disorder: a comparison of African Americans and Caucasians in the Genomic Psychiatry Cohort. *Am J Med Genet B Neuropsychiatr Genet* 2016;171:546-55.
156. Quattrone D, Di Forti M, Gayer-Anderson C et al. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. *Psychol Med* 2019;49:1378-91.
157. Veling W, Selten JP, Mackenbach JP et al. Symptoms at first contact for psychotic disorder: comparison between native Dutch and ethnic minorities. *Schizophr Res* 2007;95:30-8.
158. Heinz A, Deserno L, Reininghaus U. Urbanicity, social adversity and psychosis. *World Psychiatry* 2013;12:187-97.
159. Vassos E, Pedersen CB, Murray RM et al. Meta-analysis of the association of urbanicity with schizophrenia. *Schizophr Bull* 2012;38:1118-23.
160. Kelly BD, O'Callaghan E, Waddington JL et al. Schizophrenia and the city: a review of literature and prospective study of psychosis and urbanicity in Ireland. *Schizophr Res* 2010;116:75-89.
161. Scott J, Chant D, Andrews G et al. Psychotic-like experiences in the general community: the correlates of CIDI psychosis screen items in an Australian sample. *Psychol Med* 2006;36:231-8.
162. van Os J, Hanssen M, Bijl RV et al. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. *Arch Gen Psychiatry* 2001;58:663-8.
163. DeVlyder JE, Kelleher I, Lalane M et al. Association of urbanicity with psychosis in low- and middle-income countries. *JAMA Psychiatry* 2018;75:678-86.
164. Matheson SL, Shepherd AM, Pinchbeck RM et al. Childhood adversity in schizophrenia: a systematic meta-analysis. *Psychol Med* 2013;43:225-38.
165. Varese F, Smeets F, Drukker M et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. *Schizophr Bull* 2012;38:661-71.
166. Morgan C, Gayer-Anderson C. Childhood adversities and psychosis: evidence, challenges, implications. *World Psychiatry* 2016;15:93-102.
167. Palmier-Claus JE, Berry K, Bucci S et al. Relationship between childhood adversity and bipolar affective disorder: systematic review and meta-analysis. *Br J Psychiatry* 2016;209:454-9.
168. Gibson LE, Alloy LB, Ellman LM. Trauma and the psychosis spectrum: a review of symptom specificity and explanatory mechanisms. *Clin Psychol Rev* 2016;49:92-105.
169. Borroni S, Somma A, Krueger RF et al. Assessing the relationships between self-reports of childhood adverse experiences and DSM-5 alternative model of personality disorder traits and domains: a study on Italian community-dwelling adults. *Personal Ment Health* 2019;13:180-9.
170. Velikonja T, Fisher HL, Mason O et al. Childhood trauma and schizotypy: a systematic literature review. *Psychol Med* 2015;45:947-63.
171. Marconi A, Di Forti M, Lewis CM et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. *Schizophr Bull* 2016;42:1262-9.
172. Moraleda E, Ramirez Lopez J, Fernandez-Calderon F et al. Personality traits among the various profiles of substance use disorder patients: new evidence using the DSM-5 Section III Framework. *Eur Addict Res* 2019;25:238-47.
173. Ragazzi TCC, Shuhama R, Menezes PR et al. Cannabis use as a risk factor for psychotic-like experiences: a systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. *Early Interv Psychiatry* 2018;12:1013-23.
174. Szoke A, Galliot AM, Richard JR et al. Association between cannabis use and schizotypal dimensions - a meta-analysis of cross-sectional studies. *Psychiatry Res* 2014;219:58-66.
175. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. *Acta Psychiatr Scand* 2007;115:304-9.
176. Foti DJ, Kotov R, Guey LT et al. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. *Am J Psychiatry* 2010;167:987-93.
177. Quattrone D, Ferraro L, Tripoli G et al. Cannabis-associated symptom profiles in patients with first episode psychosis and population controls. *bioRxiv* 2019;577932.
178. Ringen PA, Nesvag R, Helle S et al. Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder. *Psychol Med* 2016;46:3127-36.
179. Seddon JL, Birchwood M, Copello A et al. Cannabis use is associated with increased psychotic symptoms and poorer psychosocial functioning in first-episode psychosis: a report from the UK National EDEN Study. *Schizophr Bull* 2016;42:619-25.
180. Bora E, Pantelis C. Meta-analysis of cognitive impairment in first-episode bipolar disorder: comparison with first-episode schizophrenia and healthy controls. *Schizophr Bull* 2015;41:1095-104.
181. Bora E, Pantelis C. Social cognition in schizophrenia in comparison to bipolar disorder: a meta-analysis. *Schizophr Res* 2016;175:72-8.
182. Carpenter WT, Bustillo JR, Thaker GK et al. The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11. *Psychol Med* 2009;39:2025-42.
183. Rosell DR, Futterman SE, McMaster A et al. Schizotypal personality disorder: a current review. *Curr Psychiatry Rep* 2014;16:452.
184. Green MF, Horan WP, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. *World Psychiatry* 2019;18:146-61.
185. Kuswanto C, Chin R, Sum MY et al. Shared and divergent neurocognitive impairments in adult patients with schizophrenia and bipolar disorder: whither the evidence? *Neurosci Biobehav Rev* 2016;61:66-89.
186. Lynham AJ, Hubbard L, Tansey KE et al. Examining cognition across the bipolar/schizophrenia diagnostic spectrum. *J Psychiatry Neurosci* 2018;43:170076.
187. Reichenberg A, Harvey PD, Bowie CR et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. *Schizophr Bull* 2009;35:1022-9.
188. Sheffield JM, Karcher NR, Barch DM. Cognitive deficits in psychotic disorders: a lifespan perspective. *Neuropsychol Rev* 2018;28:509-33.
189. de Gracia Dominguez M, Viechtbauer W, Simons CJ et al. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. *Psychol Bull* 2009;135:157-71.
190. Dibben CR, Rice C, Laws K et al. Is executive impairment associated with schizophrenic syndromes? A meta-analysis. *Psychol Med* 2009;39:381-92.
191. Ventura J, Thames AD, Wood RC et al. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. *Schizophr Res* 2010;121:1-14.
192. Ettinger U, Mohr C, Gooding DC et al. Cognition and brain function in schizotypy: a selective review. *Schizophr Bull* 2015;41(Suppl. 2):S417-26.
193. Siddi S, Petretto DR, Preti A. Neuropsychological correlates of schizotypy: a systematic review and meta-analysis of cross-sectional studies. *Cogn Neuropsychiatry* 2017;22:186-212.
194. Steffens M, Meyhofer I, Fassbender K et al. Association of schizotypy with dimensions of cognitive control: a meta-analysis. *Schizophr Bull* 2018;44(Suppl. 2):S512-24.
195. Barch DM, Pagliaccio D, Luking K. Mechanisms underlying motivational deficits in psychopathology: similarities and differences in depression and schizophrenia. *Curr Top Behav Neurosci* 2016;27:411-49.
196. Deserno L, Heinz A, Schlagenhauf F. Computational approaches to schizophrenia: a perspective on negative symptoms. *Schizophr Res* 2017;186:46-54.
197. Green MF, Horan WP, Barch DM et al. Effort-based decision making: a novel approach for assessing motivation in schizophrenia. *Schizophr Bull* 2015;41:1035-44.
198. Gold JM, Waltz JA, Matveeva TM et al. Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence. *Arch Gen Psychiatry* 2012;69:129-38.
199. Strauss GP, Waltz JA, Gold JM. A review of reward processing and motivational impairment in schizophrenia. *Schizophr Bull* 2014;40(Suppl. 2):S107-16.
200. Alloy LB, Olinio T, Freed RD et al. Role of reward sensitivity and processing in major depressive and bipolar spectrum disorders. *Behav Ther* 2016;47:600-21.
201. Johnson SL, Edge MD, Holmes MK et al. The behavioral activation system and mania. *Annu Rev Clin Psychol* 2012;8:243-67.
202. Fervaha G, Remington G. Neuroimaging findings in schizotypal personality disorder: a systematic review. *Prog Neuropsychopharmacol Biol Psychiatry* 2013;43:96-107.
203. Hajima SV, Van Haren N, Cahn W et al. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. *Schizophr Bull* 2013;39:1129-38.
204. Haukvik UK, Tamnes CK, Soderman E et al. Neuroimaging hippocampal subfields in schizophrenia and bipolar disorder: a systematic review and meta-analysis. *J Psychiatr Res* 2018;104:217-26.
205. Mathew I, Gardin TM, Tandon N et al. Medial temporal lobe structures and hippocampal subfields in psychotic disorders: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. *JAMA Psychiatry* 2014;71:769-77.
206. Boos HB, Aleman A, Cahn W et al. Brain volumes in relatives of patients with

- schizophrenia: a meta-analysis. *Arch Gen Psychiatry* 2007;64:297-304.
207. De Peri L, Crescini A, Deste G et al. Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies. *Curr Pharm Des* 2012;18:486-94.
 208. van Erp TGM, Walton E, Hibar DP et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. *Biol Psychiatry* 2018;84:644-54.
 209. Vicens V, Radua J, Salvador R et al. Structural and functional brain changes in delusional disorder. *Br J Psychiatry* 2016;208:153-9.
 210. Yu K, Cheung C, Leung M et al. Are bipolar disorder and schizophrenia neuroanatomically distinct? An anatomical likelihood meta-analysis. *Front Hum Neurosci* 2010;4:189.
 211. Francis AN, Mothi SS, Mathew IT et al. Callosal abnormalities across the psychosis dimension: Bipolar Schizophrenia Network on Intermediate Phenotypes. *Biol Psychiatry* 2016;80:627-35.
 212. Dong D, Wang Y, Chang X et al. Shared abnormality of white matter integrity in schizophrenia and bipolar disorder: a comparative voxel-based meta-analysis. *Schizophr Res* 2017;185:41-50.
 213. Dong D, Wang Y, Chang X et al. Dysfunction of large-scale brain networks in schizophrenia: a meta-analysis of resting-state functional connectivity. *Schizophr Bull* 2018;44:168-81.
 214. Meda SA, Ruano G, Windemuth A et al. Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia. *Proc Natl Acad Sci USA* 2014;111:E2066-75.
 215. Ongur D, Lundy M, Greenhouse I et al. Default mode network abnormalities in bipolar disorder and schizophrenia. *Psychiatry Res* 2010;183:59-68.
 216. O'Neill A, Mechelli A, Bhattacharyya S. Dysconnectivity of large-scale functional networks in early psychosis: a meta-analysis. *Schizophr Bull* 2019;45:579-90.
 217. Satterthwaite TD, Vandekar SN, Wolf DH et al. Connectome-wide network analysis of youth with psychosis-spectrum symptoms. *Mol Psychiatry* 2015;20:1508-15.
 218. Sheffield JM, Kandala S, Burgess GC et al. Cingulo-opercular network efficiency mediates the association between psychotic-like experiences and cognitive ability in the general population. *Biol Psychiatry Cogn Neurosci Neuroimaging* 2016;1:498-506.
 219. Sheffield JM, Kandala S, Tamminga CA et al. Transdiagnostic associations between functional brain network integrity and cognition. *JAMA Psychiatry* 2017;74:605-13.
 220. Li Y, Li WX, Xie DJ et al. Grey matter reduction in the caudate nucleus in patients with persistent negative symptoms: an ALE meta-analysis. *Schizophr Res* 2018;192:9-15.
 221. Radua J, Schmidt A, Borgwardt S et al. Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis. *JAMA Psychiatry* 2015;72:1243-51.
 222. Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. *Neurosci Biobehav Rev* 2011;35:537-55.
 223. Husain M, Roiser JP. Neuroscience of apathy and anhedonia: a transdiagnostic approach. *Nat Rev Neurosci* 2018;19:470-84.
 224. Yang X, Cao D, Liang X et al. Schizophrenia symptomatic associations with diffusion tensor imaging measured fractional anisotropy of brain: a meta-analysis. *Neuroradiology* 2017;59:699-708.
 225. Glahn DC, Ragland JD, Abramoff A et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. *Hum Brain Mapp* 2005;25:60-9.
 226. Fusar-Poli P. Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis. *J Psychiatry Neurosci* 2012;37:106-12.
 227. Wolf DH, Satterthwaite TD, Calkins ME et al. Functional neuroimaging abnormalities in youth with psychosis spectrum symptoms. *JAMA Psychiatry* 2015;72:456-65.
 228. Gonzalez-Ortega I, de Los Mozos V, Echeburua E et al. Working memory as a predictor of negative symptoms and functional outcome in first episode psychosis. *Psychiatry Res* 2013;206:8-16.
 229. Hazlett EA, Rothstein EG, Ferreira R et al. Sensory gating disturbances in the spectrum: similarities and differences in schizotypal personality disorder and schizophrenia. *Schizophr Res* 2015;161:283-90.
 230. Wan L, Thomas Z, Pisipati S et al. Inhibitory deficits in prepulse inhibition, sensory gating, and antisaccade eye movement in schizotypy. *Int J Psychophysiol* 2017;114:47-54.
 231. Hermens DF, Chitty KM, Kaur M. Mismatch negativity in bipolar disorder: a neurophysiological biomarker of intermediate effect? *Schizophr Res* 2018;191:132-9.
 232. Javitt DC, Lee M, Kantrowitz JT et al. Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia. *Schizophr Res* 2018;191:51-60.
 233. Lepock JR, Mizrahi R, Korostil M et al. Event-related potentials in the clinical high-risk (CHR) state for psychosis: a systematic review. *Clin EEG Neurosci* 2018;49:215-25.
 234. Randeniya R, Oestreich LKL, Garrido MI. Sensory prediction errors in the continuum of psychosis. *Schizophr Res* 2018;191:109-22.
 235. Taylor SF, Stern ER, Gehring WJ. Neural systems for error monitoring: recent findings and theoretical perspectives. *Neuroscientist* 2007;13:160-72.
 236. Martin EA, McCleery A, Moore MM et al. ERP indices of performance monitoring and feedback processing in psychosis: a meta-analysis. *Int J Psychophysiol* 2018;132:365-78.
 237. Foti D, Kotov R, Bromet E et al. Beyond the broken error-related negativity: functional and diagnostic correlates of error processing in psychosis. *Biol Psychiatry* 2012;71:864-72.
 238. Foti D, Perlman G, Hajcak G et al. Impaired error processing in late-phase psychosis: four-year stability and relationships with negative symptoms. *Schizophr Res* 2016;176:520-6.
 239. Vancampfort D, Vansteelandt K, Correll CU et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. *Am J Psychiatry* 2013;170:265-74.
 240. Vancampfort D, Wampers M, Mitchell AJ et al. A meta-analysis of cardiometabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. *World Psychiatry* 2013;12:240-50.
 241. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. *Mol Psychiatry* 2016;21:1696-709.
 242. Kohler CA, Freitas TH, Maes M et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. *Acta Psychiatr Scand* 2017;135:373-87.
 243. Comes AL, Papiol S, Mueller T et al. Proteomics for blood biomarker exploration of severe mental illness: pitfalls of the past and potential for the future. *Transl Psychiatry* 2018;8:160.
 244. Green MJ, Matheson SL, Shepherd A et al. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. *Mol Psychiatry* 2011;16:960-72.
 245. Munkholm K, Vinberg M, Kessing LV. Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. *Mol Psychiatry* 2016;21:216-28.
 246. Chen C, Cheng L, Grennan K et al. Two gene co-expression modules differentiate psychotics and controls. *Mol Psychiatry* 2013;18:1308-14.
 247. de Baumont A, Maschietto M, Lima L et al. Innate immune response is differentially dysregulated between bipolar disease and schizophrenia. *Schizophr Res* 2015;161:215-21.
 248. Zhao Z, Xu J, Chen J et al. Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder. *Mol Psychiatry* 2015;20:563-72.
 249. Gandal MJ, Haney JR, Parikshak NN et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. *Science* 2018;359:693-7.
 250. Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. *Biol Psychiatry* 2008;64:89-97.
 251. Hess JL, Tylee DS, Barve R et al. Transcriptome-wide mega-analyses reveal joint dysregulation of immunologic genes and transcription regulators in brain and blood in schizophrenia. *Schizophr Res* 2016;176:114-24.
 252. Hess JL, Tylee DS, Barve R et al. Transcriptomic abnormalities in peripheral blood in bipolar disorder, and discrimination of the major psychoses. *Schizophr Res* (in press).
 253. Leirer DJ, Iyegbe CO, Di Forti M et al. Differential gene expression analysis in blood of first episode psychosis patients. *Schizophr Res* 2019;209:88-97.
 254. Teroganova N, Girshkin L, Suter CM et al. DNA methylation in peripheral tissue of schizophrenia and bipolar disorder: a systematic review. *BMC Genet* 2016;17:27.
 255. De Clercq B, Verbeke L, De Caluwe E et al. Understanding adolescent personality pathology from growth trajectories of childhood oddity. *Dev Psychopathol* 2017;29:1403-11.
 256. Fagel S, de Sonneville L, van Engeland H et al. School-associated problem behavior in childhood and adolescence and development of adult schizotypal symptoms: a follow-up of a clinical cohort. *J Abnorm Child Psychol* 2014;42:813-23.
 257. Matheson SL, Vijayan H, Dickson H et al. Systematic meta-analysis of child-

- hood social withdrawal in schizophrenia, and comparison with data from at-risk children aged 9-14 years. *J Psychiatr Res* 2013;47:1061-8.
258. Olin SS, Raine A, Cannon TD et al. Childhood behavior precursors of schizotypal personality disorder. *Schizophr Bull* 1997;23:93-103.
 259. Wolff S, Townshend R, McGuire RJ et al. 'Schizoid' personality in childhood and adult life. II: Adult adjustment and the continuity with schizotypal personality disorder. *Br J Psychiatry* 1991;159:620-9.
 260. Poulton R, Caspi A, Moffitt TE et al. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. *Arch Gen Psychiatry* 2000;57:1053-8.
 261. Zammit S, Kounali D, Cannon M et al. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. *Am J Psychiatry* 2013;170:742-50.
 262. Dominguez MD, Wichers M, Lieb R et al. Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study. *Schizophr Bull* 2011;37:84-93.
 263. Jaaskelainen E, Juola P, Hirvonen N et al. A systematic review and meta-analysis of recovery in schizophrenia. *Schizophr Bull* 2013;39:1296-306.
 264. Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. *Psychiatr Serv* 2005;56:735-42.
 265. AlAqeel B, Margolese HC. Remission in schizophrenia: critical and systematic review. *Harv Rev Psychiatry* 2012;20:281-97.
 266. Grilo CM, Sanislow CA, Gunderson JG et al. Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. *J Consult Clin Psychol* 2004;72:767-75.
 267. Gignac A, McGirr A, Lam RW et al. Recovery and recurrence following a first episode of mania: a systematic review and meta-analysis of prospectively characterized cohorts. *J Clin Psychiatry* 2015;76:1241-8.
 268. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. *Psychol Med* 2006;36:1349-62.
 269. Skodol AE, Oldham JM, Bender DS et al. Dimensional representations of DSM-IV personality disorders: relationships to functional impairment. *Am J Psychiatry* 2005;162:1919-25.
 270. Tohen M, Zarate CA Jr, Hennen J et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. *Am J Psychiatry* 2003;160:2099-107.
 271. Kotov R, Fochtmann L, Li K et al. Declining clinical course of psychotic disorders over the two decades following first hospitalization: evidence from the Suffolk County Mental Health Project. *Am J Psychiatry* 2017;174:1064-74.
 272. Hopwood CJ, Morey LC, Donnellan MB et al. Ten-year rank-order stability of personality traits and disorders in a clinical sample. *J Pers* 2013;81:335-44.
 273. Austin SF, Mors O, Secher RG et al. Predictors of recovery in first episode psychosis: the OPUS cohort at 10 year follow-up. *Schizophr Res* 2013;150:163-8.
 274. Hegelstad WT, Larsen TK, Auestad B et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. *Am J Psychiatry* 2012;169:374-80.
 275. Shibre T, Medhin G, Alem A et al. Long-term clinical course and outcome of schizophrenia in rural Ethiopia: 10-year follow-up of a population-based cohort. *Schizophr Res* 2015;161:414-20.
 276. Ventura J, Helleman GS, Thames AD et al. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. *Schizophr Res* 2009;113:189-99.
 277. Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull* 2010;36:71-93.
 278. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd ed. *Am J Psychiatry* 2004;161:1-56.
 279. Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. *World Psychiatry* 2017;16:251-65.
 280. Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. *Lancet* 2011;378:1306-15.
 281. Jakobsen KD, Skyum E, Hashemi N et al. Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review. *J Psychopharmacol* 2017;31:397-405.
 282. Fusar-Poli P, Papanastasiou E, Stahl D et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. *Schizophr Bull* 2015;41:892-9.
 283. Aleman A, Enriquez-Geppert S, Knegtering H et al. Moderate effects of non-invasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: meta-analysis of controlled trials. *Neurosci Biobehav Rev* 2018;89:111-8.
 284. Lincoln T, Pedersen A. An overview of the evidence for psychological interventions for psychosis: results from meta-analyses. *Clin Psychol Eur* 2019;1: e31407.
 285. Frojan-Parga MX, Nunez de Prado-Gordillo M, Alvarez-Iglesias A et al. Functional behavioral assessment-based interventions on adults' delusions, hallucinations and disorganized speech: a single case meta-analysis. *Behav Res Ther* 2019;120:103444.
 286. Almerie MQ, Okba Al Marhi M, Jawoosh M et al. Social skills programmes for schizophrenia. *Cochrane Database Syst Rev* 2015;9:CD009006.
 287. Lutgens D, Garipey G, Malla A. Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis. *Br J Psychiatry* 2017;210:324-32.
 288. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management. London: National Institute for Health and Care Excellence, 2014.
 289. Turner DT, van der Gaag M, Karyotaki E et al. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. *Am J Psychiatry* 2014;171:523-38.
 290. Kirchner SK, Roeh A, Nolden J et al. Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review. *NPJ Schizophr* 2018;4:20.
 291. Nordentoft M, Thorup A, Petersen L et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. *Schizophr Res* 2006;83:29-40.
 292. Cella M, Preti A, Edwards C et al. Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis. *Clin Psychol Rev* 2017;52: 43-51.
 293. Granholm E, Holden J, Link PC et al. Randomized clinical trial of cognitive behavioral social skills training for schizophrenia: improvement in functioning and experiential negative symptoms. *J Consult Clin Psychol* 2014;82:1173-85.
 294. Battagliese G, Caccetta M, Luppino OI et al. Cognitive-behavioral therapy for externalizing disorders: a meta-analysis of treatment effectiveness. *Behav Res Ther* 2015;75:60-71.
 295. Watts SE, Turnell A, Kladnitski N et al. Treatment-as-usual (TAU) is anything but usual: a meta-analysis of CBT versus TAU for anxiety and depression. *J Affect Disord* 2015;175:152-67.
 296. Regier DA, Narrow WE, Clarke DE et al. DSM-5 field trials in the United States and Canada, Part II: Test-retest reliability of selected categorical diagnoses. *Am J Psychiatry* 2013;170:59-70.
 297. Narrow WE, Clarke DE, Kuramoto SJ et al. DSM-5 field trials in the United States and Canada, Part III: Development and reliability testing of a cross-cutting symptom assessment for DSM-5. *Am J Psychiatry* 2013;170:71-82.
 298. Reed GM, Sharan P, Rebello TJ et al. The ICD-11 developmental field study of reliability of diagnoses of high-burden mental disorders: results among adult patients in mental health settings of 13 countries. *World Psychiatry* 2018;17:174-86.
 299. Quilty LC, Ayeast L, Chmielewski M et al. The psychometric properties of the Personality Inventory for DSM-5 in an APA DSM-5 field trial sample. *Assessment* 2013;20:362-9.
 300. Al-Dajani N, Gralnick TM, Bagby RM. A psychometric review of the Personality Inventory for DSM-5 (PID-5): current status and future directions. *J Pers Assess* 2016;98:62-81.
 301. Chmielewski M, Ruggero CJ, Kotov R et al. Comparing the dependability and associations with functioning of the DSM-5 Section III trait model of personality pathology and the DSM-5 Section II personality disorder model. *Personal Disord* 2017;8:228-36.
 302. Suzuki T, Griffin SA, Samuel DB. Capturing the DSM-5 alternative personality disorder model traits in the Five-Factor Model's nomological net. *J Pers* 2017;85:220-31.
 303. Morey LC, Hopwood CJ, Markowitz JC et al. Comparison of alternative models for personality disorders, II: 6-, 8- and 10-year follow-up. *Psychol Med* 2012;42:1705-13.
 304. Rosenman S, Korten A, Medway J et al. Dimensional vs. categorical diagnosis in psychosis. *Acta Psychiatr Scand* 2003;107:378-84.
 305. Hanlon FM, Yeo RA, Shaff NA et al. A symptom-based continuum of psychosis explains cognitive and real-world functional deficits better than traditional diagnoses. *Schizophr Res* 2019;208:344-52.
 306. Sabharwal A, Szekely A, Kotov R et al. Transdiagnostic neural markers of emotion-cognition interaction in psychotic disorders. *J Abnorm Psychol* 2016;125:907-22.
 307. First MB, Pincus HA, Levine JB et al. Clinical utility as a criterion for revising psychiatric diagnoses. *Am J Psychiatry* 2004;161:946-54.
 308. Keeley JW, Reed GM, Roberts MC et al. Developing a science of clinical util-

- ity in diagnostic classification systems field study strategies for ICD-11 mental and behavioral disorders. *Am Psychol* 2016;71:3-16.
309. Mullins-Sweatt SN, Widiger TA. Clinical utility and DSM-V. *Psychol Assess* 2009;21:302-12.
 310. Reed GM, Keeley JW, Rebello TJ et al. Clinical utility of ICD-11 diagnostic guidelines for high-burden mental disorders: results from mental health settings in 13 countries. *World Psychiatry* 2018;17:306-15.
 311. Rottman BM, Ahn WK, Sanislow CA et al. Can clinicians recognize DSM-IV personality disorders from five-factor model descriptions of patient cases? *Am J Psychiatry* 2009;166:427-33.
 312. Sprock J. Dimensional versus categorical classification of prototypic and nonprototypic cases of personality disorder. *J Clin Psychol* 2003;59:991-1014.
 313. Glover NG, Crego C, Widiger TA. The clinical utility of the Five Factor Model of personality disorder. *Personal Disord* 2012;3:176-84.
 314. Lowe JR, Widiger TA. Clinicians' judgments of clinical utility: a comparison of the DSM-IV with dimensional models of general personality. *J Pers Disord* 2009;23:211-29.
 315. Morey LC, Skodol AE, Oldham JM. Clinician judgments of clinical utility: a comparison of DSM-IV-TR personality disorders and the alternative model for DSM-5 personality disorders. *J Abnorm Psychol* 2014;123:398-405.
 316. Samuel DB, Widiger TA. Clinicians' judgments of clinical utility: a comparison of the DSM-IV and five-factor models. *J Abnorm Psychol* 2006;115:298-308.
 317. Samuel DB, Widiger TA. Clinicians' use of personality disorder models within a particular treatment setting: a longitudinal comparison of temporal consistency and clinical utility. *Personal Ment Health* 2011;5(1).
 318. Moscicki EK, Clarke DE, Kuramoto SJ et al. Testing DSM-5 in routine clinical practice settings: feasibility and clinical utility. *Psychiatr Serv* 2013;64:952-60.
 319. Bornstein RF, Natoli AP. Clinical utility of categorical and dimensional perspectives on personality pathology: a meta-analytic review. *Personal Disord* 2019;10:479-90.
 320. Widiger TA. Considering the research: Commentary on "The trait-type dialectic: construct validity, clinical utility, and the diagnostic process". *Personal Disord* 2019;10:215-9.
 321. Waszczuk MA, Zimmerman M, Ruggero C et al. What do clinicians treat: diagnoses or symptoms? The incremental validity of a symptom-based, dimensional characterization of emotional disorders in predicting medication prescription patterns. *Compr Psychiatry* 2017;79:80-8.
 322. First MB, Rebello TJ, Keeley JW et al. Do mental health professionals use diagnostic classifications the way we think they do? A global survey. *World Psychiatry* 2018;17:187-95.
 323. First MB, Westen D. Classification for clinical practice: how to make ICD and DSM better able to serve clinicians. *Int Rev Psychiatry* 2007;19:473-81.
 324. Flanagan EH, Blashfield RK. Increasing clinical utility by aligning the DSM and ICD with clinicians' conceptualizations. *Prof Psychol Res Pr* 2010;41:474-81.
 325. Taylor D. Prescribing according to diagnosis: how psychiatry is different. *World Psychiatry* 2016;15:224-5.
 326. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med* 2015;372:793-5.
 327. Nichols JH, Christenson RH, Clarke W et al. Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing. *Clin Chim Acta* 2007;379:14-28.
 328. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychol Rep* 1962;10:799-812.
 329. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa, 1983.
 330. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984.
 331. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull* 1987;13:261-76.
 332. Suzuki T. Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. *Psychopharmacol Bull* 2011;44:18-31.
 333. Woods SW, Walsh BC, Powers AR et al. Reliability, validity, epidemiology, and cultural variation of the Structured Interview for Psychosis-Risk Syndromes (SIPS) and the Scale of Psychosis-Risk Symptoms (SOPS). In: Li H, Shapiro DI, Seidman LJ (eds). *Handbook of attenuated psychosis syndrome across cultures*. Cham: Springer, 2019:85-113.
 334. Dazzi F, Shafer A, Lauriola M. Meta-analysis of the Brief Psychiatric Rating Scale - Expanded (BPRS-E) structure and arguments for a new version. *J Psychiatr Res* 2016;81:140-51.
 335. Reininghaus U, Bohnke JR, Hosang G et al. Evaluation of the validity and utility of a transdiagnostic psychosis dimension encompassing schizophrenia and bipolar disorder. *Br J Psychiatry* 2016;209:107-13.
 336. Shafer A, Dazzi F. Meta-analysis of the Positive and Negative Syndrome Scale (PANSS) factor structure. *J Psychiatr Res* 2019;115:113-20.
 337. Reininghaus U, Priebe S, Bentall RP. Testing the psychopathology of psychosis: evidence for a general psychosis dimension. *Schizophr Bull* 2013;39:884-95.
 338. Reed GM, First MB, Kogan CS et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. *World Psychiatry* 2019;18:3-19.
 339. Mortimer AM. Symptom rating scales and outcome in schizophrenia. *Br J Psychiatry* 2007;191(Suppl. 50):s7-14.
 340. van Erp TG, Preda A, Nguyen D et al. Converting positive and negative symptom scores between PANSS and SAPS/SANS. *Schizophr Res* 2014;152:289-94.
 341. Kirkpatrick B, Strauss GP, Nguyen L et al. The Brief Negative Symptom Scale: psychometric properties. *Schizophr Bull* 2011;37:300-5.
 342. Strauss GP, Gold JM. A psychometric comparison of the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale. *Schizophr Bull* 2016;42:1384-94.
 343. Fulford D, Pearson R, Stuart BK et al. Symptom assessment in early psychosis: the use of well-established rating scales in clinical high-risk and recent-onset populations. *Psychiatry Res* 2014;220:1077-83.
 344. Tso IF, Taylor SF, Grove TB et al. Factor analysis of the Scale of Prodromal Symptoms: data from the Early Detection and Intervention for the Prevention of Psychosis Program. *Early Interv Psychiatry* 2017;11:14-22.
 345. Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms and profiles. Burlington: University of Vermont Research Center for Children, Youth, and Families, 2001.
 346. Achenbach TM, Rescorla LA. Manual for the ASEBA adult forms and profiles. Burlington: University of Vermont, 2003.
 347. Andreasen NC, Carpenter WT Jr, Kane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. *Am J Psychiatry* 2005;162:441-9.
 348. Krueger RF, Derringer J, Markon KE et al. Initial construction of a maladaptive personality trait model and inventory for DSM-5. *Psychol Med* 2012;42:1879-90.
 349. Mark W, Touloupoulou T. Psychometric properties of "Community Assessment of Psychic Experiences": review and meta-analyses. *Schizophr Bull* 2015;42:34-44.
 350. Stefanis NC, Hanssen M, Smirnis NK et al. Evidence that three dimensions of psychosis have a distribution in the general population. *Psychol Med* 2002;32:347-58.
 351. Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. *Arch Gen Psychiatry* 1982;39:789-94.
 352. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? *BMJ* 1980;280:66-8.
 353. McElroy E, Belsky J, Carragher N et al. Developmental stability of general and specific factors of psychopathology from early childhood to adolescence: dynamic mutualism or p-differentiation? *J Child Psychol Psychiatry* 2018;59:667-75.
 354. Olino TM, Bufferd SJ, Dougherty LR et al. The development of latent dimensions of psychopathology across early childhood: stability of dimensions and moderators of change. *J Abnorm Child Psychol* 2018;46:1373-83.
 355. Snyder HR, Young JF, Hankin BL. Strong homotypic continuity in common psychopathology-, internalizing-, and externalizing-specific factors over time in adolescents. *Clin Psychol Sci* 2017;5:98-110.
 356. Forbes MK, Tackett JL, Markon KE et al. Beyond comorbidity: toward a dimensional and hierarchical approach to understanding psychopathology across the life span. *Dev Psychopathol* 2016;28:971-86.
 357. Preacher KJ, Rucker DD, MacCallum RC et al. Use of the extreme groups approach: a critical reexamination and new recommendations. *Psychol Methods* 2005;10:178-92.
 358. Uher R, Rutter M. Basing psychiatric classification on scientific foundation: problems and prospects. *Int Rev Psychiatry* 2012;24:591-605.
 359. Kotov R, Ruggero CJ, Krueger RF et al. The perils of hierarchical exclusion rules: a further word of caution. *Depress Anxiety* 2018;35:903-4.
 360. Kraemer HC, Noda A, O'Hara R. Categorical versus dimensional approaches to diagnosis: methodological challenges. *J Psychiatr Res* 2004;38:17-25.
 361. Michelini G, Barch DM, Tian Y et al. Delineating and validating higher-order dimensions of psychopathology in the Adolescent Brain Cognitive Development (ABCD) study. *Transl Psychiatry* 2019;9:261.
 362. Kotov R, Leong SH, Mojtabai R et al. Boundaries of schizoaffective disorder: revisiting Kraepelin. *JAMA Psychiatry* 2013;70:1276-86.

DOI:10.1002/wps.20730